1. Institute of Medicine, Committee on Advancing Pain Research, Care, and Education. (2011). Relieving pain in America: A blueprint for transforming prevention, care, education and research (pp. 2–6). Prepublication copy. Washington, DC: National Academies Press.
2. Census Bureau Call Center (personal communication, September 23, 2011).
3. Tsang, A., Von Korff, M., Lee, S., Alonso, J., Karam, E., Angermeyer, M. C., et al. (2008). Common chronic pain conditions in developed and developing countries: Gender and age differences and comorbidity with depression-anxiety disorders. The Journal of Pain, 9(10), 883–891.
4. Brown, A. (2012, April 7). Chronic pain rates shoot up until Americans reach late 50s. Retrieved from http://www.gallup.com/poll/154169/Chronic-Pain-Rates-Shoot-Until-Americans-Reach-Late-50s.aspx
5. Portenoy, R. K., Ugarte, C., Fuller, I., & Haas, G. (2004). Population-based survey of pain in the United States: Differences among white, African American, and Hispanic subjects. The Journal of Pain, 5(6), 317–328.
6. Institute of Medicine, Committee on Advancing Pain Research, Care, and Education. (2011). Relieving pain in America: A blueprint for transforming prevention, care, education and research (pp. 2–6). Prepublication copy. Washington, DC: National Academies Press.
7. Krueger, A. B., & Stone, A. A. (2008). Assessment of pain: A community-based diary survey in the USA. The Lancet, 371(9623), 1519–1525.
8. Breivik, H., Collett, B., Ventafridda, V., Cohen, R., & Gallacher, D. (2006). Survey of chronic pain in Europe: Prevalence, impact on daily life, treatment. European Journal of Pain, 10(4), 287–333.
9. R. Portenoy (personal communication, September 3, 2008).
10. Breivik, H., Collett, B., Ventafridda, V., Cohen, R., & Gallacher, D. (2006). Survey of chronic pain in Europe: Prevalence, impact on daily life, treatment. European Journal of Pain, 10 (4), 287–333.
11. L. Webster (personal communication, March 22, 2012).
12. Institute of Medicine, Committee on Advancing Pain Research, Care, and Education. (2011). Relieving pain in America: A blueprint for transforming prevention, care, education and research (pp. 2–27). Prepublication copy. Washington, DC: National Academies Press.
13. Institute of Medicine, Committee on Advancing Pain Research, Care, and Education. (2011). Relieving pain in America: A blueprint for transforming prevention, care, education and research (pp. 2–29). Prepublication copy. Washington, DC: National Academies Press.
14. Breslau, N., Schultz, L., Lipton, R., Peterson, E., & Welch, K. M. A. (2012). Migraine headaches and suicide attempt. Headache: The Journal of Head and Face Pain, 52(5), 723–731.
15. International Association for the Study of Pain. (2012, August 28). Unrelieved pain is a major global healthcare problem. Retrieved from http://www.iasp-pain.org/AM/Template.cfm?Section=Press_Release&Template=/CM/ContentDisplay.cfm&ContentID=2908
16. H. Heit (personal communication, September 20, 2011).
17. P. Konowitz (personal communication, November 15, 2009).
18. D. Biro (personal communication, September 19, 2011).
19. M. Cooper (personal communication, Sept. 29, 2011).
20. K. Binkley (personal communication, September 18, 2011).
21. Lamas, D., & Rosenbaum, L. (2012). Painful inequities—Palliative care in developing countries. New England Journal of Medicine, 366(3), 199–201.
22. Institute of Medicine, Committee on Advancing Pain Research, Care, and Education. (2011). Relieving pain in America: A blueprint for transforming prevention, care, education and research (pp. 4–17). Prepublication copy. Washington, DC: National Academies Press.
23. J. Martin (personal communication, October 4, 2011).
24. M. Zylka (personal communication, November 2, 2011).
25. Watt-Watson, J., McGillion, M., Hunter, J., Choiniere, M., Clark, A. J., Dewar, A., et al. (2009). A survey of prelicensure pain curricula in health science faculties in Canadian universities. Pain Research & Management, 14(6), 439–444.
26. Briggs, E. V., Carr, E. C. J., & Whittaker, M. S. (2011). Survey of undergraduate pain curricula for healthcare professionals in the United Kingdom. European Journal of Pain, 15(8), 789–795.
27. J. Prescott (personal communication, October 19, 2011).
28. Mezei, L., Murinson, B. B., & Johns Hopkins Pain Curriculum Development Team. (2011). Pain education in North American medical schools. The Journal of Pain, 12(12), 1199–1208.
29. Institute of Medicine, Committee on Advancing Pain Research, Care, and Education. (2011). Relieving pain in America: A blueprint for transforming prevention, care, education and research (pp. 4–14). Prepublication copy. Washington, DC: National Academies Press.
30. Blumenthal, D., Gokhale, M., Campbell, E. G., & Weissman, J. S. (2001). Preparedness for clinical practice: Reports of graduating residents at academic health centers. Journal of the American Medical Association, 286(9), 1027–1034.
31. Upshur, C. C., Luckmann, R. S., & Savageau, J. A. (2006). Primary care provider concerns about management of chronic pain in community clinic populations. Journal of General Internal Medicine, 21(6), 652–655.
32. Association of American Medical Colleges. (2006). Medical school graduation questionnaire: All schools report. Retrieved from https://www.aamc.org/download/90062/data/gq-2006.pdf
33. Association of American Medical Colleges. (2010). GQ Medical school graduation questionnaire: All schools summary report. Retrieved from https://www.aamc.org/download/140716/data/2010_gq_all_schools.pdf
34. Association of American Medical Colleges. (2011). GQ Medical school graduation questionnaire: All schools summary report. Retrieved from https://www.aamc.org/download/263712/data/gq-2011.pdf
35. O’Rorke, J. E., Chen, I., Genao, I., Panda, M., & Cykert, S. (2007). Physicians’ comfort in caring for patients with chronic nonmalignant pain. American Journal of Medical Sciences, 333(2), 93–100.
36. J. Loeser (personal communication, September 16, 2011).
37. Murinson, B. B., Nenortas, E., Mayer, R. S., Mezei, L., Kozachik, S., Nesbit, S., et al. (2011). A new program in pain medicine for medical students: Integrating core curriculum knowledge with emotional and reflective development. Pain Medicine, 12, 186–195.
38. American Association of Nurse Anesthetists, American Academy of Pain Medicine, American Headache Society, American Pain Foundation, American Pain Society, American Society of Anesthesiologists, et al. (2011, June 29). Consumers, health professionals and advocates join to hail release of landmark Institute of Medicine report on advancing pain research, care and education. Statement released at the Institute of Medicine press conference, Washington, DC.
39. Burgoyne, D. S. (2007). Prevalence and economic implications of chronic pain. Managed Care, 16(2 Supplement 3), 2–4.
40. Pletcher, M. J., Kertesz, S. G., Kohn, M. A., & Gonzales, R. (2008). Trends in opioid prescribing by race/ethnicity for patients seeking care in US emergency departments. Journal of the American Medical Association, 299(1),70–78.
41. Institute of Medicine, Committee on Advancing Pain Research, Care, and Education. (2011). Relieving pain in America: A blueprint for transforming prevention, care, education and research (pp. C.1–C.45). Prepublication copy. Washington, DC: National Academies Press.
42. Institute of Medicine, Committee on Advancing Pain Research, Care, and Education. (2011). Relieving pain in America: A blueprint for transforming prevention, care, education and research (pp. 2–33). Prepublication copy. Washington, DC: National Academies Press.
43. Institute of Medicine, Committee on Advancing Pain Research, Care, and Education. (2011). Relieving pain in America: A blueprint for transforming prevention, care, education and research (p. C-4). Prepublication copy. Washington, DC: National Academies Press.
44. Y. Shir (personal communication, November 12, 2009).
45. National Institutes of Health. (n.d.). The NIH Almanac—Appropriations (section 2). Retrieved from http://www.nih.gov/about/almanac/appropriations/part2.htm
46. National Institutes of Health Research Portfolio Online Reporting Tools (RePORT). (2012, February 13). Estimates of funding for various research, condition, and disease categories (RCDC). Retrieved from http://report.nih.gov/rcdc/categories/
47. R. Myles (personal communication, February 23, 2012).
48. R. Myles (personal communication, October 19, 2012).
49. Porter, L. (2012, October 22). Federally-funded pain research portfolio. Slides presented at the Second Meeting of the Interagency Pain Research Coordinating Committee, Bethesda, MD. Retrieved from http://videocast.nih.gov/pastevents.asp
50. D. Bradshaw (personal communication, September 20, 2011).
51. D. Bradshaw (personal communication, February 23, 2012).
52. National Institutes of Health Research Portfolio Online Reporting Tools (RePORT). (2012, February 13). Estimates of funding for various research, condition, and disease categories (RCDC). Retrieved from http://report.nih.gov/rcdc/categories/
53. National Institutes of Health. (n.d.). The NIH Almanac: Appropriations (section 2). Retrieved March 15, 2012, from http://www.nih.gov/about/almanac/appropriations/part2.htm
54. L. Porter (personal communication, February 22, 2012).
55. J. Kusiak (personal communication, September 26, 2011).
56. National Institutes of Health Research Portfolio Online Reporting Tools (RePORT). (2012, February 13). Estimates of funding for various research, condition, and disease categories (RCDC). Retrieved from http://report.nih.gov/rcdc/categories/
57. National Institutes of Health. (n.d.). The NIH Almanac: Appropriations (section 2). Retrieved March 15, 2012, from http://www.nih.gov/about/almanac/appropriations/part2.htm
58. R. Saner (personal communication, September 22, 2011).
59. S. Report No. 112-84 at 114(2012).
60. S. Fishman (personal communication, October 10, 2011).
61. P. Pizzo (personal communication, September 22, 2011).
62. K. Foley (personal communication, September 21, 2011.)
63. C. Steinberg (personal communication, September 22, 2011).
64. Institute of Medicine, Committee on Advancing Pain Research, Care, and Education. (2011). Relieving pain in America: A blueprint for transforming prevention, care, education and research (pp. 2–7). Prepublication copy. Washington, DC: National Academies Press.
65. Rawal, N. (2007). Postoperative pain treatment for ambulatory surgery. Best Practice & Research Clinical Anaesthesiology, 21(1), 129–148.
66. Schug, S. A., & Chong, C. (2009). Pain management after ambulatory surgery. Current Opinion in Anaesthesiology, 22(6), 738–743.
67. Institute of Medicine, Committee on Advancing Pain Research, Care, and Education. (2011). Relieving pain in America: A blueprint for transforming prevention, care, education and research (pp. 1–25). Prepublication copy. Washington, DC: National Academies Press.
68. Kehlet, H., Jensen, T. S., & Woolf, C. J. (2006). Persistent postsurgical pain: Risk factors and prevention. The Lancet, 367(9522), 1618–1625.
69. Wu, C. L., & Raja, S. N. (2011). Treatment of acute postoperative pain. The Lancet, 377(9784), 2215–2225.
70. Institute of Medicine, Committee on Advancing Pain Research, Care, and Education. (2011). Relieving pain in America: A blueprint for transforming prevention, care, education and research (pp. 2–7). Prepublication copy. Washington, DC: National Academies Press.
71. Green, C. R., Hart-Johnson, T., & Loeffler, D. R. (2011). Cancer-related chronic pain: Examining quality of life in diverse cancer survivors. Cancer, 117(9), 1994–2003.
72. Deandrea, S., Montanaari, M., Moja, L., & Apolone, G. (2008). Prevalence of undertreatment in cancer pain. A review of published literature. Annals of Oncology, 19(12), 1985–1991.
73. Institute of Medicine, Committee on Advancing Pain Research, Care, and Education. (2011). Relieving pain in America: A blueprint for transforming prevention, care, education and research (pp. 2–5). Prepublication copy. Washington, DC: National Academies Press.
74. C. Woolf (personal communication, September 26, 2011).
75. Tracey, I., & Bushnell, M. C. (2009). How neuroimaging studies have challenged us to rethink: Is chronic pain a disease? The Journal of Pain, 10(11), 1113–1120.
1. International Association for the Study of Pain. (n.d.). IASP taxonomy: Pain. Retrieved from http://www.iasp-pain.org/Content/NavigationMenu/GeneralResourceLinks/PainDefinitions/default.htm
2. Institute of Medicine, Committee on Advancing Pain Research, Care, and Education. (2011). Relieving pain in America: A blueprint for transforming prevention, care, education and research (pp. 1–17). Prepublication copy. Washington, DC: National Academies Press.
3. Melzack, R. (2005). Evolution of the neuromatrix theory of pain. The Prithvi Raj lecture: Presented at the third World Congress of World Institute of Pain, Barcelona, 2004. Pain Practice, 5(2), 85–94.
4. Institute of Medicine, Committee on Advancing Pain Research, Care, and Education. (2011). Relieving pain in America: A blueprint for transforming prevention, care, education and research (pp. 1–18). Prepublication copy. Washington, DC: National Academies Press.
5. deCharms, R. C., Maeda, F., Glover, G. H., Ludlow, D., Pauly, J. M., Soneji, D., et al. (2005). Control over brain activation and pain learned by using real-time functional MRI. Proceedings of the National Academy of Sciences, 102(51), 18626–18631.
6. Thernstrom, M. (2010). The pain chronicles: Cures, myths, mysteries, prayers, diaries, brain scans, healing, and the science of suffering (p. 5). New York: Farrar, Straus and Giroux.
7. Scarry, E. (1985). The body in pain: The making and unmaking of the world (p. 7). New York: Oxford University Press.
8. Von Hehn, C. A., Baron, R., & Woolf, C. (2012). Deconstructing the neuropathic pain phenotype to reveal neural mechanisms. Neuron, 73(4), 638–652.
9. Andrews, N. (2012, July 9). Moving pain treatments forward: NIH Pain Consortium Symposium. Retrieved from http://www.painresearchforum.org/news/17877-moving-pain-treatments-forward-nih-pain-consortium-symposium
10. C. Woolf (personal communication, July 16, 2012).
11. Costigan, M., Scholz, J., & Woolf, C. J. (2009). Neuropathic pain: A maladaptive response of the nervous system to damage. Annual Review of Neuroscience, 32, 1–32.
12. Scholz, J., & Woolf, C. J. (2002). Can we conquer pain? [Review]. Nature Neuroscience, 5 (Supplement), 1062–1067.
13. Brenner, G. J., & Woolf, C. J. (2007). Mechanisms of chronic pain. In D. E. Longnecker, D. L. Brown, M. F. Newman, & W. M Zapol (Eds.), Anesthesiology (pp. 2000–2019). New York: McGraw Hill Companies.
14. Brenner, G. J., & Woolf, C. J. (2007). Mechanisms of chronic pain. In D. E. Longnecker, D. L. Brown, M. F. Newman, & W. M Zapol (Eds.), Anesthesiology (pp. 2000–2019). New York: McGraw Hill Companies.
15. Costigan, M., Scholz, J., & Woolf, C. J. (2009). Neuropathic pain: A maladaptive response of the nervous system to damage. Annual Review of Neuroscience, 32, 1–32.
16. Haanpää, M., & Treede, R. D. (2010). Diagnosis and classification of neuropathic pain. PAIN: Clinical Updates, 18(7), 1–6.
17. Braz, J. M., Sharif-Naeini, R., Vogt, D., Kriegstein, A., Alvarez-Buylia, A., Rubenstein, J. L., et al. (2012). Forebrain GABAergic neuron precursors integrate into adult spinal cord and reduce injury-induced neuropathic pain. Neuron, 74(4), 663–675.
18. G. Brenner (personal communication, October 28, 2010).
19. Fishman, S., & Berger, L. (2001). The war on pain (p. 118). New York: HarperCollins.
20. Woolf, C. J., & Ma, Q. (2007). Nociceptors—noxious stimulus detectors. Neuron, 55, 353–364.
21. Brenner, G. J., & Woolf, C. J. (2007). Mechanisms of chronic pain. In D. E. Longnecker, D. L. Brown, M. F. Newman, & W. M. Zapol (Eds.), Anesthesiology (pp. 2000–2019). New York: McGraw Hill Companies.
22. Patapoutian, A., Tate, S., & Woolf, C. J. (2009). Transient receptor potential channels: Targeting pain at the source. Nature Reviews Drug Discovery, 8, 55–68.
23. Bohlen, C. J., Chesler, A. T., Sharif-Naeini, R., Medzihradszky, K. F., Zhou, S., King, D., et al. (2011). A heteromeric Texas coral snake toxin targets acid-sensing ion channels to produce pain. Nature, 479(7373), 410–414.
24. Talkington, M. (2011, November 18). Lone star snakes reveal unexpected role for acid-sensing channels in pain. Retrieved from http://www.painresearchforum.org/search/site/Lone%20Star%20Snakes
25. Wortman, M. (2012). Where does it hurt? Researchers are getting to the molecular details of pain’s circuitry to answer the question with real specificity. Howard Hughes Medical Institute Bulletin, 25(1), 32–33, 48.
26. Miller, A. N., & Long, S. B. (2012). Crystal structure of the human two-pore domain potassium channel K2P1 [Abstract]. Science, 335(6067), 432–436.
27. Brohawn, S. G., del Marmol, J., & MacKinnon, R. (2012). Crystal structure of the human K2P TRAAK, a lipid-and mechano-sensitive K+ ion channel [Abstract]. Science, 335(6067), 436–441.
28. Kim, S. E., Coste, B., Chadha, A., Cook, B., & Patapoutian, A. (2012). The role of Drosophila Piezo in mechanical nociception [Abstract]. Nature, 483(7388), 209–212.
29. Coste, B., Xiao, B., Santos, J. S., Syeda, R., Grandl, J., Kim, S. E., et al. (2012). Piezo proteins are pore-forming subunits of mechanically activated channels. Nature, 483(7388), 176–181.
30. Talkington, M. (2012, February 23). Novel ion channel senses painful touch. Retrieved from http://www.painresearchforum.org/news/13812-novel-ion-channel-senses-painful-touch?search_term=novel%20ion%20channel
31. Porreca, F. (2011, October 17). Cancer biology seminar series: Descending modulatory circuits and cancer pain [Video file]. Retrieved from http://streaming.biocom.arizone.edu/people/?id=11499
32. Beecher, H. K. (1956). Relationship of significance of wound to pain experienced. Journal of the American Medical Association, 161(17), 1609–1613.
33. von Mourik, O. (2006, April 2). Penfield’s homunculus and the mystery of phantom limbs. Retrieved from http://journalism.nyu.edu/publishing/archives/annotate/node/270
34. G. Brenner (personal communication, March 13, 2012).
35. NOVA online. (n.d.). Secrets of the mind: Brain-mapping pioneers. Retrieved from http://www.pbs.org/wgbh/nova/mind/prob_pio.html
36. Blakeslee, S., & Blakeslee, M. (2007). The body has a mind of its own: How body maps in your brain help you do (almost) everything better (pp. 17–22). New York: Random House.
37. Ramachandran, V. S., Rogers-Ramachandran, D., & Stewart, M. I. (1992). Perceptual correlates of massive cortical reorganization. Science, 258(5085), 1159–1160.
38. Apkarian, A. V., Sosa, Y., Sonty, S., Levy, R. M., Harden, R. N., Parrish, T. B., et al. (2004). Chronic back pain is associated with decreased prefrontal and thalamic gray matter density. Journal of Neuroscience, 24(46), 10410–10415.
39. Latremoliere., & Woolf, C. (2009). Central sensitization: A generator of pain hypersensitivity by central neural plasticity [Critical review]. The Journal of Pain, 10(9), 895–926.
40. Brenner, G. J., & Woolf, C. J. (2007). Mechanisms of chronic pain. In D. E. Longnecker, D. L. Brown, M. F. Newman, & W. M. Zapol (Eds.), Anesthesiology (pp. 2000–2019). New York: McGraw Hill Companies.
41. Woolf, C. J. (2007). Central sensitization: Uncovering the relation between pain and plasticity. Anesthesiology, 106(4), 864–867.
42. Woolf, C. J. (2010, September). Central sensitization: How plasticity produces pain . Lecture presented at the 13th World Congress on Pain, Montreal, Canada.
43. Apkarian, A. V., Baliki, M. N., & Geha, P. Y. (2009). Towards a theory of chronic pain. Progress in Neurobiology, 87, 81–97.
44. Apkarian, A. V., Bushnell, M. C., Treede, R. D., & Zubieta, J. K. (2005). Human brain mechanisms of pain perception and regulation in health and disease. European Journal of Pain, 9(4), 463–484.
45. Gottschalk, A., Smith, D. S., Jobes, D. R., Kennedy, S. K., Lally, S. E., Noble, V. E., et al. (1998). Preemptive epidural analgesia and recovery from radical prostatectomy: A randomized controlled trial. Journal of the American Medical Association, 279(14), 1076–1082.
46. L. Watkins (personal communication, October 28, 2009).
47. Tracey, I., & Bushnell, M. C. (2009). How neuroimaging studies have challenged us to rethink: Is chronic pain a disease? The Journal of Pain, 10(11), 1113–1120.
48. Brown, J. E., Chatterjee, N., Younger, J., & Mackey, S. (2011). Towards a physiology-based measure of pain: Patterns of human brain activity distinguish painful from non-painful thermal stimulation. PLoS ONE, 6(9), e24124.
49. White, T. (2011, September 13). Does that hurt? Objective way to measure pain being developed at Stanford [Press release]. Retrieved from http://med.stanford.edu/ism/2011/september/pain.html
50. S. Mackey (personal communication, April 14, 2012).
51. Miller, G. (2009, January). Brain scans of pain raise questions for the law. Science, 323, 195.
52. White, T. (2011, September 13). Does that hurt? Objective way to measure pain being developed at Stanford [Press release]. Retrieved from http://med.stanford.edu/ism/2011/september/pain.html
53. Apkarian, A. V., Sosa, Y., Sonty, S., Levy, R. M., Harden, R. N., Parrish, T. B., et al. (2004). Chronic back pain is associated with decreased prefrontal and thalamic gray matter density. Journal of Neuroscience, 24(46), 10410–10415.
54. Kuchinad, A., Schweinhardt, P., Seminowicz, D. A., Wood, P. B., Chizh, B. A., & Bushnell, M. C. (2007). Accelerated brain gray matter loss in fibromyalgia patients: Premature aging of the brain? Journal of Neuroscience, 27(15), 4004–4007.
55. Seminowicz, D. A., Labus, J. S., Bueller, J. A., Tillisch, K., Naliboff, B. D., & Bushnell, M. C. (2010). Regional gray matter density changes in brains of patients with irritable bowel syndrome. Gastroenterology, 139(1), 48–57.
56. Schmidt-Wilcke, T., Leinisch, E., Straube, A., Kampfe, N., Draganski, B., Diener, H. C., et al. (2005). Gray matter decrease in patients with chronic tension type headache. Neurology, 65, 1483–1486.
57. Da Silva, A. F., Becerra, L., Pendse, G., Chizh, B., Tully, S., & Borsook, D. (2008). Colocalized structural and functional changes in the cortex of patients with trigeminal neuropathic pain. PLoS ONE, 3(10), e3396.
58. Draganski, B., Moser, T., Lummel, N., Ganssbauer, S., Bogdahn, U., Haas, F., et al. (2006). Decrease of thalamic gray matter following limb amputation. Neuroimage, 31(3), 951–957.
59. Wrigley, P. J., Gustin, S. M., Macey, P. M., Nash, P. G., Gandevia, S. C., Macefield, V. G., et al. (2009). Anatomical changes in human motor cortex and motor pathways following complete thoracic spinal cord injury. Cerebral Cortex, 19(1), 224–232.
60. Younger, J. W., Chu, L. F., D’Arcy, N. T., Trott, K. E., Jastrzab, L. E., & Mackey, S. C. (2011). Prescription opioid analgesics rapidly change the human brain. PAIN, 152(8), 1803–1810.
61. Tracey, I., & Bushnell, M. C. (2009). How neuroimaging studies have challenged us to rethink: Is chronic pain a disease? The Journal of Pain, 10(11), 1113–1120.
62. G. Scherr (personal communication, October 13, 2010).
63. G. Scherr (personal communication, February 5, 2012).
64. Schweinhardt, P., Kuchinad, A., Pukall, C. F., & Bushnell, M. C. (2008). Increased gray matter density in young women with chronic vulvar pain. PAIN, 140(3), 411–419.
65. Nikolajsen, L., Brandsborg, B., Lucht, U., Jensen, T. S., & Kehlet, H. (2006). Chronic pain following total hip arthroplasty: A nationwide questionnaire study. Acta Anaesthesiologica Scandinavica, 50, 495–500.
66. Rodriguez-Raecke, R., Niemeier, A., Ihle, K., Ruether, W., & May, A. (2009). Brain gray matter decrease in chronic pain is the consequence and not the cause of pain. Journal of Neuroscience, 29(44), 13746–13750.
67. Gwilym, S. E., Filippini, N., Douaud, G., Carr, A. J., & Tracey, I. (2010). Thalamic atrophy associated with painful osteoarthritis of the hip is reversible after arthroplasty: A longitudinal voxel-based-morphometric study. Arthritis & Rheumatism, 62(10), 2930–2940.
68. Seminowicz, D. A., Wideman, T. H., Naso, L., Hatami-khoroushahi, Z., Fallatah, S., Ware, M. A., et al. (2011). Effective treatment of chronic low back pain in humans reverses abnormal brain anatomy and function. Journal of Neuroscience, 31(20), 7540–7550.
69. Graceley, R. H., Geisser, M. E., Giesecke, T., Grant, M. A. B., Petske, F., Williams, D. A., et al. (2004). Pain catastrophizing and neural responses to pain among persons with fibromyalgia. Brain, 127, 835–843.
70. Baliki, M. N., Chialvo, D. R., Geha, P. Y., Levy, R. M., Harden, R. N., Parrish, T. B., et al. (2006). Chronic pain and the emotional brain: Specific brain activity associated with spontaneous fluctuations of intensity of chronic back pain. Journal of Neuroscience, 26(47), 12165–12173.
71. Apkarian, A. V., Bushnell, M. C., Treede, R. D., & Zubieta, J. K. (2005). Human brain mechanisms of pain perception and regulation in health and disease. European Journal of Pain, 9(4), 463–484.
72. Schweinhardt, P., Glynn, C., Brooks, J., McQuay, H., Jack, T., Chessell, I., et al. (2006). An fMRI study of cerebral processing of brush-evoked allodynia in neuropathic pain patients. Neuroimage, 32(1), 256–265.
73. Apkarian, A. V., Baliki, M. N., & Geha, P. Y. (2009). Towards a theory of chronic pain. Progress in Neurobiology, 87, 81–97.
74. D. Borsook (personal communication, July 1, 2010).
75. DaSilva, A. F., Becerra, L., Pendse, G., Chizh, B., Tully, S., & Borsook, D. (2008). Colocalized structural and functional changes in the cortex of patients with trigeminal neuropathic pain. PLoS ONE, 3(10), e3396.
76. Borras, M. C., Becerra, L., Ploghaus, A., Gostic, J. M., DaSilva, A., Gonzalez, R. G., et al. (2004). fMRI measurement of CNS responses to naloxone infusion and subsequent mild noxious thermal stimuli in healthy volunteers. Journal of Neurophysiology, 91(6), 2723–2733.
77. Borsook, D. (2012, August). Imaging opioid effects on the brain—from preclinical to postclinical. Paper presented at the International Association for the Study of Pain’s 14th World Congress on Pain, Milan, Italy. Abstract retrieved from http://www.abstracts2view.com/iasp/sessionindex.php
78. Langford, D. J., Bailey, A. L., Chanda, M. L., Clarke, S. E., Drummond, T. E., Echols, S., et al. (2010). Coding of facial expressions of pain in the laboratory mouse. Nature Methods, 7, 447–449.
79. Keating, S. C. J., Thomas, A. A., Flecknell, P. A., & Leach, M. C. (2012). Evaluation of EMLA cream for preventing pain during tattooing of rabbits: Changes in physiological, behavioural and facial expression responses. PLoS ONE, 7(9), e44437.
80. Ashraf, A. B., Lucey, S., Cohn, J. F., Chen, T., Ambadar, Z., Prkachin, K., et al. (2009). The painful face—pain expression recognition using active appearance models. Image and Vision Computing, 27(12), 1788–1796.
81. K. Prkachin (personal communication, October 21, 2010).
82. Kappesser, J., Williams, A. C., & Prkachin, K. (2006). Testing two accounts of pain underestimation. PAIN, 124(1–2), 109–116.
83. Melzack, R. (n.d.). The McGill Pain Questionnaire. Retrieved from http://www.cebp.nl/?NODE=154
84. D. Price (personal communication, October 21, 2010).
85. R. Staud (personal communication, September 21, 2010).
86. R. Jamison (personal communication, February 14, 2011).
87. Marceau, L. D., Link, C., Jamison R. N., & Carolan, S. (2007). Electronic diaries as a tool to improve pain management: Is there any evidence? Pain Medicine, 8(Supplements s3), S101–S109.
88. Jamison, R. N., Raymond, S. A., Levine, J. G., Slawsby, E. A., Nedeljkovic, S. S., & Katz, N. P. (2001). Electronic diaries for monitoring chronic pain: 1-year validation study. PAIN, 91(3), 277–285.
89. Scholz, J., Mannion, R. J., Hord, D. E., Griffin, R. S., Rawal, B., Zheng, H., et al. (2009). A novel tool for the assessment of pain: Validation in low back pain. PLoS Medicine, 6(4), e1000047.
90. Prkachin, K. M., & Craig, K. D. (1995). Expressing pain: The communication and interpretation of facial pain signals. Journal of Nonverbal Behavior, 19(4), 191–205.
91. Prkachin, K. M., Solomon, P., Hwang, T., & Mercer, S. R. (2001). Does experience influence judgments of pain behaviour? Evidence from relatives of pain patients and therapists. Pain Research & Management, 6(2), 105–112.
92. K. Prkachin (personal communication, October 21, 2010).
93. Kappesser, J., Williams, A. C., & Prkachin, K. (2006). Testing two accounts of pain underestimation. PAIN, 124(1–2), 109–116.
94. Martel, M. O., Thibault, P., & Sullivan, M. J. (2011). Judgments about pain intensity and pain genuineness: The role of pain behavior and judgmental heuristics. The Journal of Pain, 12(4), 468–475.
95. K. Craig (personal communication, October 26, 2010).
1. Nielsen, C. S., Staud, R., & Price, D. D. (2009). Individual differences in pain sensitivity: Measurement, causation and consequences. The Journal of Pain, 10(3), 231–237.
2. M. Rowbotham (personal communication, November 11, 2010).
3. Thyregod, H. G., Rowbotham, M. C., Peters, M., Possehn, J., Berro, M., & Petersen, K. L. (2007). Natural history of pain following herpes zoster. PAIN, 128, 148–156.
4. National Diabetes Information Clearinghouse. (2009, February). What are diabetic neuropathies? Retrieved from http://diabetes.niddk.nih.gov/dm/pubs/neuropathies/index.aspx
5. O’Hare, J. A., Abuaisha, F., & Geoghegan, M. (1994). Prevalence and forms of neuropathic morbidity in 800 diabetics [Abstract]. Irish Journal of Medical Science, 163(3), 132–135.
6. J. Mogil (personal communication, September 24, 2012).
7. C. Woolf (personal communication, February 15, 2012).
8. Alvan, G., Bechtel, P., Iselius, L., & Gundert-Remy, U. (1990). Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. European Journal of Clinical Pharmacology, 39(6), 533–537.
9. P. Costa (personal communication, November 11, 2010).
10. J. & T. Blocker (personal communication, November 6, 2010).
11. Weiss, J., Pyrski, M., Jacobi, E., Bufe, B., Willnecker, V., Schick, B., et al. (2011). Loss-of-function mutations in sodium channel Nav1.7 cause anosmia. Nature, 472, 186–190.
12. J. & T. Blocker (personal communication, November 6, 2010).
13. Cox, J. J., Reimann, F., Nicholas, A. K., Thornton, G., Roberts, E., Springell, K., et al. (2006). An SCN9A channelopathy causes congenital inability to experience pain. Nature, 444, 894–898.
14. R. Staud (personal communication, October 21, 2010).
15. S. Waxman (personal communication, September 25, 2012).
16. Faber, C. G., Hoeijmakers, J. G. J., Ahn, H. S., Cheng, X., Han, C., Choi, J. S., et al. (2012). Gain of function Nav1.7 mutations in idiopathic small fiber neuropathy. Annals of Neurology, 71(1), 26–39.
17. Reimann, F., Cox, J. J., Belfer, A., Diatchenko, L., Zaykin, D. V., McHale, D. P., et al. (2010). Pain perception is altered by a nucleotide polymorphism in SCN9A. Proceedings of the National Academy of Sciences, 107(11), 5148–5153.
18. P. Costa (personal communication, November 11, 2010).
19. S. Waxman (personal communication, November 4, 2010).
20. Drenth, J. P. H., te Morsche, R. H. M., Guillet, G., Taieb, A., Kirby, R. L., & Jansen, J. B. M. J. (2005). SCN9A mutations define primary erythermalgia as a neuropathic disorder of voltage gated sodium channels. The Journal of Investigative Dermatology, 124, 1333–1338.
21. Legroux-Crespel, E., Sassolas, B., Guillet, G., Kupfer, I., Dupre, D., & Misery, L. (2003). Treatment of familial erythermalgia with the association of lidocaine and mexiletine. Annales de Dermatologie et de Vénéréologie, 130(4), 429–433.
22. Fischer, T. A., Gilmore, E. S., Estacion, M., Eastman, E., Taylor, S., Melanson, M., et al. (2009). A novel Nav 1.7 mutation producing carbamazepine-responsive erythromelalgia. Annals of Neurology, 65(6), 733–741.
23. Cummins, T. R., Dib-Hajj, S. D., & Waxman, S. G. (2004). Electrophysiological properties of mutant Nav 1.7 sodium channels in a painful inherited neuropathy. Journal of Neuroscience, 24(38), 8232–8236.
24. Dib-Hajj, S. D., Cummins, T. R., Black, J. A., & Waxman, S. G. (2010). Sodium channels in normal and pathological pain. Annual Review of Neuroscience, 33, 325–347.
25. Dib-Hajj, S. D., Cummins, T. R., Black, J. A., & Waxman, S. G. (2007). From genes to pain: Nav 1.7 and human pain disorders. Trends in Neuroscience, 30(11), 555–563.
26. Black, J. A., Nikolajsen, L., Kroner, K., Jensen, T. S., & Waxman, S. G. (2008). Multiple sodium channel isoforms and mitogen-activated protein kinases are present in painful human neuromas. Annals of Neurology, 64(6), 644–653.
27. S. Waxman (personal communication, September 25, 2012).
28. Mogil, J. S., Wilson, S. G., Bon, K., Lee, S. E., Chung, K., Raber, P., et al. (1999). Heritability of nociception I: Responses of 11 inbred mouse strains on 12 measures of nociception. PAIN, 80(1), 67–82.
29. Mogil, J. S. (1999). The genetic mediation of individual differences in sensitivity to pain and its inhibition. Proceedings of the National Academy of Sciences, 96, 7744–7751.
30. MacGregor, A. J., Andrew, T., Sambrook, P. N., & Spector, T. D. (2004). Structural, psychological and genetic influences on low back and neck pain: A study of adult female twins. Arthritis Care & Research, 51(2), 160–167.
31. Norbury, T. A., MacGregor, A. J., Urwin, J., Spector, T. D., & McMahon, S. B. (2007). Heritability of responses to painful stimuli in women: A classical twin study. Brain, 130, 3041–3049.
32. Nielsen, C. S., Stubhaug, A., Price, D. D., Vassend, O., Czajkowski, N., & Harris, J. R. (2008). Individual differences in pain sensitivity: Genetic and environmental contributions. PAIN, 136(1), 21–29.
33. Hartvigsen, J., Nielsen, J., Kyvik, K. O., Fejer, R., Vach, W., Iachine, I., et al. (2009). Heritability of spinal pain and consequences of spinal pain: A comprehensive genetic epidemiologic analysis using a population-based sample of 15,328 twins ages 20–71 years. Arthritis Care and Research, 61(10), 1343–1351.
34. Markkula, R., Jarvinen, P., Leino-Arjas, P., Koskenvuo, M., Kalso, E., & Kaprio, J. (2009). Clustering of symptoms associated with fibromyalgia in a Finnish twin cohort. European Journal of Pain, 13(7), 744–750.
35. Mogil, J. S. (1999). The genetic mediation of individual differences in sensitivity to pain and its inhibition. Proceedings of the National Academy of Sciences, 96, 7744–7751.
36. Spector, T. D., & MacGregor, A. J. (2004). Risk factors for osteoarthritis: Genetics. Osteoarthritis and Cartilage, 12(Supplement 1), 39–44.
37. J. Mogil (personal communication, September 24, 2012).
38. Talkington, M. (2011, October 17). Epigenetic downregulation of GABA signaling perpetuates pain. Retrieved from http://www.pain-researchforum.org/news/10272-epigenetic-downregulation-gaba-signaling-perpetuates-pain
39. Zhang, Z., Cai, Y. Q., Zou, F., Bie, B., & Pan, Z. Z. (2011). Epigenetic suppression of GAD65 expression mediates persistent pain. Nature Medicine, 17(11), 1448–1455.
40. Langford, D. J., Bailey, A. L., Chanda, M. L., Clarke, S. E., Drummond, T. E., Echols, S., et al. (2010). Coding of facial expressions of pain in the laboratory mouse. Nature Methods, 7, 447–449.
41. Mogil, J. (2012, February). The nature and nurture of pain. Paper presented at the 10th International Association for the Study of Pain Research Symposium, Miami Beach, FL.
42. Costigan, M., Belfer, I., Griffin, R. S., Dai, F., Barrett, L. B., Coppola, G., et al. (2010). Multiple chronic pain states are associated with a common amino acid-changing allele in KCNS1. Brain, 133(9), 2519–2527.
43. Neely, G. G., Hess, A., Costigan, M., Keene, A. C., Goulas, S., Langeslag, M., et al. (2010). A genome-wide Drosophila screen for heat nociception identifies α2δ3 as an evolutionarily conserved pain gene. Cell, 143(4), 628–638.
44. M. Moskowitz (personal communication, November 29, 2010).
45. Gardner, K. L. (2006). Genetics of migraine: An update. Headache: The Journal of Head and Face Pain, 46(Supplement 1), S19–S24.
46. Anttila, V., Stefansson, H., Kallela, M., Todt, U., Terwindt, G. M., Calafato, M. S., et al. (2010). Genome-wide association study of migraine implicates a common susceptibility variant on 8q22.1 [Letter]. Nature Genetics, 42, 869–873.
47. Tegeder, I., Costigan, M., Griffin, R. S., Abele, A., Belfer, I., Schmidt, H., et al. (2006). GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence. Nature Medicine, 12(11), 1269–1277.
48. Tegeder, I., Adolph, J., Schmidt, H., Woolf, C. J., Geisslinger, G., & Lotsch, J. (2008). Reduced hyperalgesia in homozygous carriers of a GTP cyclohydrolase 1 haplotype. European Journal of Pain, 12(8), 1069–1077.
49. Cromie, W. J. (2006, November 16). Sensitivity to pain explained. Harvard University Gazette. Retrieved from http://news.harvard.edu/gazette/story/2006/11/sensitivity-to-pain-explained
50. Lotsch, J., Belfer, I., Kirchhof, A., Mishra, B. K., Max, M. B., Doehring, A., et al. (2007). Reliable screening for a pain-protective haplotype in the GTP cyclohydrolase 1 gene (GCH1) through the use of 3 or fewer single nucleotide polymorphisms. Clinical Chemistry, 53(6), 1010–1015.
51. L. Diatchenko (personal communication, November 5, 2010).
52. W. Maixner (personal communication, November 1, 2010).
53. Maixner, W. (2012, February). Unraveling persistent pain conditions with genetic and phenotypic biomarkers. Paper presented at the 10th International Association for the Study of Pain Research Symposium, Miami Beach, FL.
54. Tchivileva, I. E., Lim, P. F., Smith, S. B., Slade, G. D., Diatchenko, L., McLean, S. A., et al. (2010). Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: A randomized, double-blind, placebo-controlled, crossover pilot study. Pharmacogenetics and Genomics, 20(4), 239–248.
55. Light, K. C., Bragdon, E. E., Grewen, K. M., Brownley, K. A., Girdler, S. S., & Maixner, W. (2009). Adrenergic dysregulation and pain with and without acute beta-blockage in women with fibromyalgia and temporomandibular disorder. The Journal of Pain, 10(5), 542–552.
56. Emery, E. C., Young, G. T., Berrocoso, E. M., Chen, L., & McNaughton, P. A. (2011). HCN2 ion channels play a central role in inflammatory and neuropathic pain. Science, 333(6048), 1462–1466.
57. University of Cambridge. (2011, September 9). Gene that controls chronic pain identified. Research lays groundwork for the development of new, targeted pain medications [Press release]. Retrieved from http://www.bbsrc.ac.uk/news/health/2011/110909-pr-gene-that-controls-pain.aspx
58. Bond, C., LaForge, K.S., Tian, M., Melia, D., Zhang, S., Borg, L., et al. (1998). Single-nucleotide polymorphism in the human mu opioid receptor gene alters B-endorphin binding and activity: Possible implications for opiate addiction. Proceedings of the National Academy of Sciences, 95(16), 9608–9613.
59. Pan, Y-X. (2005). Diversity and complexity of the mu opioid receptor gene: Alternative pre-mRNA splicing and promoters. DNA and Cell Biology, 24(11), 736–750.
60. Walter, C., & Lotsch, J. (2009). Meta-analysis of the relevance of the OPRM1 118A> G genetic variant for pain treatment. PAIN, 146, 270–275.
61. University of North Carolina at Chapel Hill. (2011, November 10). Large-scale jaw pain study sheds light on pain disorders [Press release]. Retrieved from http://uncnews.unc.edu/content/view/4910/71/
62. Slade, G. D., Bair, E., By, K., Mulkey, F., Baraian, C., Rothwell, R., et al. (2011). Study methods, recruitment, sociodemographic findings, and demographic representativeness in the OPPERA study. The Journal of Pain, 12(11 Supplement), T12–T26.
1. Ayroles, J. F., Carbone, M. A., Stone, E. A., Jordan, K. W., Lyman, R. F., Magwire, M. M., et al. (2009). Systems of genetics of complex traits in Drosophila melanogaster. Nature Genetics, 41(3), 305.
2. I. Belfer (personal communication, March 7, 2012).
3. Unruh, A. M. (1996). Gender variations in clinical pain experience [Abstract]. PAIN, 65(2–3), 123–167.
4. Fillingim, R. B., King, C. D., Ribeiro-Dasilva, M. C., Rahim-Williams, B., & Riley, J. L., III. (2009). Sex, gender, and pain: A review of recent clinical and experimental findings. The Journal of Pain, 10(5), 447–485.
5. Aubrun, F., Salvi, N., Coriat, P., & Riou, B. (2005). Sex-and age-related differences in morphine requirements for postoperative pain relief [Abstract]. Anesthesiology, 103(1), 156–160.
6. LeResche, L. (2011). Defining gender disparities in pain management. Clinical Orthopaedics and Related Research, 469(7), 1871–1877.
7. Tsang, A., Von Korff, M., Lee, S., Alonso, J., Karam, E., Angermeyer, M. C., et al. (2008). Common chronic pain conditions in developed and developing countries: Gender and age differences and comorbidity with depression-anxiety disorders. The Journal of Pain, 9(10), 883–891.
8. Fillingim, R. B., King, C. D., Ribeiro-Dasilva, M. C., Rahim-Williams, B., & Riley, J. L., III. (2009). Sex, gender, and pain: A review of recent clinical and experimental findings. The Journal of Pain, 10(5), 447–485.
9. Bennett, M. I., Lee, A. J., Smith, B. H., & Torrance, N. (2006). The epidemiology of chronic pain of predominantly neuropathic origin: Results from a general population survey [Abstract]. The Journal of Pain, 7(4), 281–289.
10. National Institute of Neurological Disorders and Stroke. NINDS complex regional pain syndrome information page. Retrieved June 6, 2013, from http://www.ninds.nih.gov/disorders/reflex_sympathetic_dystrophy/reflex_sympathetic_dystrophy.htm
11. de Mos, M., De Bruijn, A. G. J., Huygen, F., Dieleman, J. P., Stricker, B. H., & Sturkenboom, M. (2007). The incidence of complex regional pain syndrome: A population-based study [Abstract]. PAIN, 129(1–2), 12–20.
12. Hall, G. C., Carroll, D., Parry, D., & McQuay, H. J. (2006). Epidemiology and treatment of neuropathic pain: The UK primary care perspective. PAIN, 122(1–2), 156–162.
13. Fillingim, R. B., King, C. D., Ribeiro-Dasilva, M. C., Rahim-Williams, B., & Riley, J. L., III. (2009). Sex, gender, and pain: A review of recent clinical and experimental findings. The Journal of Pain, 10(5), 447–485.
14. Srikanth, V. K., Fryer, J. L., Zhai, G., Winzenberg, T. M., Hosmer, D., & Jones, G. (2005). A meta-analysis of sex differences prevalence, incidence and severity of osteoarthritis [Abstract]. Osteoarthritis and Cartilage, 13(9), 769–781.
15. Christmas, C., Crespo, C. J., Franckowiak, S. C., Bathon, J. M., Bartlett, S. J., & Andersen, R. E. (2002). How common is hip pain among older adults? Results from the third national health and nutrition examination survey. The Journal of Family Practice, 51(4), 345–348.
16. Fillingim, R. B., King, C. D., Ribeiro-Dasilva, M. C., Rahim-Williams, B., & Riley, J. L., III. (2009). Sex, gender, and pain: A review of recent clinical and experimental findings. The Journal of Pain, 10(5), 447–485.
17. Fillingim, R. B., King, C. D., Ribeiro-Dasilva, M. C., Rahim-Williams, B., & Riley, JL., III. (2009). Sex, gender, and pain: A review of recent clinical and experimental findings. The Journal of Pain, 10(5), 447–485.
18. Fillingim, R. B., King, C. D., Ribeiro-Dasilva, M. C., Rahim-Williams, B., & Riley, J. L., III. (2009). Sex, gender, and pain: A review of recent clinical and experimental findings. The Journal of Pain, 10(5), 447–485.
19. Sandler, R. S. (1990). Epidemiology of irritable bowel syndrome in the United States [Abstract]. Gastroenterology, 99(2), 409–415.
20. M. Gold (personal communication, April 25, 2012).
21. Fillingim, R. B., King, C. D., Ribeiro-Dasilva, M. C., Rahim-Williams, B., & Riley, J. L., III. (2009). Sex, gender, and pain: A review of recent clinical and experimental findings. The Journal of Pain, 10(5), 447–485.
22. Darnall, B. D. (n.d.). Sex/gender disparity in pain and pain treatment: Closing the gap and meeting women’s treatment needs. Retrieved from http://www.forgrace.org/images/uploads/Gender_Disparities_in_Pain_feature.pdf
23. Ruau, D., Liu, L. Y., Clark, J. D., Angst, M. S., & Butte, A. J. (2012). Sex differences in reported pain across 11,000 patients captured in electronic medical records. The Journal of Pain, 13(3), 228–234.
24. W. Maixner (personal communication, November 1, 2010).
25. H. Bursztajn (personal communication, October 20, 2010).
26. Mogil, J. S., & Chanda, M. L. (2005). The case for the inclusion of female subjects in basic science studies of pain. PAIN, 117(1–2), 1–5.
27. Wizemann, T. M., & Pardue, M-L. (Eds.). (2001). Exploring the biological contributions to human health: Does sex matter? Washington, DC: National Academies Press.
28. Fillingim, R. B., King, C. D., Ribeiro-Dasilva, M. C., Rahim-Williams, B., & Riley, J. L., III. (2009). Sex, gender, and pain: A review of recent clinical and experimental findings. The Journal of Pain, 10(5), 447–485.
29. Greenspan, J. D., Craft, R. M., LeResche, L., Arendt-Nielsen, L., Berkley, K. J., Fillingim, R. B., et al. (2007). Studying sex and gender differences in pain and analgesia: A consensus report. PAIN, 132, S26–S45.
30. K. Berkley (personal communication, October 5, 2010).
31. Levine, F. M., & De Simone, L. L. (1991). The effects of experimenter gender on pain report in male and female subjects [Abstract]. PAIN, 44(1), 69–72.
32. Gijsbers, K., & Nicholson, F. (2005). Experimental pain thresholds influenced by sex of experimenter. Perceptual and Motor Skills, 101(3), 803–807.
33. Fillingim, R. B., Browning, A. D., Powell, T., & Wright, R. A. (2002). Sex differences in perceptual and cardiovascular responses to pain: The influence of a perceived ability manipulation [Abstract]. The Journal of Pain, 3(6), 439–445.
34. Racine, M., Tousignant-Laflamme, Y., Kloda, L. A., Dion, D., Dupuis, G., & Choiniere, M. (2012). A systematic literature review of 10 years of research on sex/gender and experimental pain perception—part I: Are there really differences between men and women? PAIN, 153(3), 602–618.
35. Fillingim, R. B., King, C. D., Ribeiro-Dasilva, M. C., Rahim-Williams, B., & Riley, J. L., III. (2009). Sex, gender, and pain: A review of recent clinical and experimental findings. The Journal of Pain, 10(5), 447–485.
36. Fillingim, R. B., King, C. D., Ribeiro-Dasilva, M. C., Rahim-Williams, B., & Riley, J.L., III. (2009). Sex, gender, and pain: A review of recent clinical and experimental findings. The Journal of Pain, 10(5), 447–485.
37. Fillingim, R. B., King, C. D., Ribeiro-Dasilva, M. C., Rahim-Williams, B., & Riley, J. L., III. (2009). Sex, gender, and pain: A review of recent clinical and experimental findings. The Journal of Pain, 10(5), 447–485.
38. Sarlani, E., Grace, E. G., Reynolds, M. A., & Greenspan, J. D. (2004). Sex differences in temporal summation of pain and aftersensations following repetitive noxious mechanical stimulation. PAIN, 109(1), 115–123.
39. Sarlani, E., & Greenspan, J. D. (2002). Gender differences in temporal summation of mechanically evoked pain [Abstract]. PAIN, 97(1), 163–169.
40. Racine, M., Tousignant-Laflamme, Y., Kloda, L. A., Dion, D., Dupuis, G., & Choiniere, M. (2012). A systematic literature review of 10 years of research on sex/gender and experimental pain perception—part 2: Do biopsychosocial factors alter pain sensitivity differently in women and men? PAIN, 153(3), 619–635.
41. J. Greenspan (personal communication, October 20, 2010).
42. Paulson, P. E., Minoshima, S., Morrow, T. J., & Casey, K. L. (1998). Gender differences in pain perception and patterns of cerebral activation during noxious heat stimulation in humans [Abstract]. PAIN, 76(1–2), 223–229.
43. Naliboff, B. D., Berman, S., Chang, L., Derbyshire, S. W. G., Suyenobu, B., Vogt, B. A., et al. (2003). Sex-related differences in IBS patients: Central processing of visceral stimuli. Gastroenterology, 124(7), 1738–1747.
44. Maleki, N., Linnman, C., Brawn, J., Burstein, R., Becerra, L., & Borsook, D. (2012). Her versus his migraine: Multiple sex differences in brain function and structure. Brain, 135(8), 2546–2559.
45. Berman, S. M., Naliboff, B. D., Suyenobu, B., Labus, J. S., Stains, J., Bueller, J. A., et al. (2006). Sex differences in regional brain response to aversive pelvic visceral stimuli [Abstract]. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 291(2), R268–R276.
46. Weisse, C. S., Sorum, P. C., & Dominguez, R. E. (2003). The influence of gender and race on physicians’ pain management decisions. The Journal of Pain, 4(9), 505–510.
47. Raftery, K. A., Smith-Coggins, R., & Chen, A. H. M. (1995). Gender-associated differences in emergency department pain management [Abstract]. Annals of Emergency Medicine, 26(4), 414–421.
48. Hoffmann, D. E., & Tarzian, A. J. (2001). The girl who cried pain: A bias against women in the treatment of pain. The Journal of Law, Medicine & Ethics, 28, 13–27.
49. Fishbain, D. A., Goldberg, M., Meagher, B. R., Steele, R., & Rosomoff, H. (1986). Male and female chronic pain patients categorized by DSM-III psychiatric diagnostic criteria [Abstract]. PAIN, 26(2), 181–197.
50. A. Oaklander (personal communication, October 6, 2010).
51. Di Cecco, R., Patel, U., & Upshur, R. E. (2002). Is there a clinically significant gender bias in post-myocardial infarction pharmacological management in the older (>60) population of a primary care practice? BMC Family Practice, 3, 8.
52. Fowler, R. A., Sabur, N., Li, P., Juurlink, D. N., Pinto, R., Hladunewich, M. A., et al. (2007). Sex-and age-based differences in the delivery and outcomes of critical care. Canadian Medical Association Journal, 177(12), 1513–1519.
53. Calderone, K. L. (1990). The influence of gender on the frequency of pain and sedative medication administered to postoperative patients. Sex Roles, 23(11), 713–725.
54. Schulman, K. A., Berlin, J. A., Harless, W., Kerner, J. F., Sistrunk, S., Gersh, B. J., et al. (1999). The effect of race and sex on physicians’ recommendations for cardiac catheterization [Abstract]. The New England Journal of Medicine, 340(8), 618–626.
55. Daly, C., Clemens, F., Lopez Sendon, J. L., Tavazzi, L., Boersma, E., Danchin, N., et al. (2006). Gender differences in the management and clinical outcome of stable angina [Abstract]. Circulation, 113(4), 490–498.
56. Roger, V. L., Farkouh, M. E., Weston, S. A., Reeder, G. S., Jacobsen, S. J., Zinsmeister, A. R., et al. (2000). Sex differences in evaluation and outcome of unstable angina [Abstract]. The Journal of the American Medical Association, 283(5), 646–652.
57. M. O’Connor (personal communication, April 6, 2012).
58. O’Connor, M. I. (2011). Implant survival, knee function and pain relief after TKA. Clinical Orthopaedics and Related Research, 469(7), 1846–1851.
59. Borkhoff, C. M., Hawker, G. A., Kreder, H. J., Glazier, R. H., Mahomed, N. N., & Wright, J. G. (2008). The effect of patients’ sex on physicians’ recommendations for total knee arthroplasty. Canadian Medical Association Journal, 178(6), 681–687.
60. Chen, E. H., Shofer, F. S., Dean, A. J., Hollander, J. E., Baxt, W. G., Robey, J. L., et al. (2008). Gender disparity in analgesic treatment of emergency department patients with acute abdominal pain. Academic Emergency Medicine, 15(5), 414–418.
61. Cleeland, C. S., Gonin, R., Hatfield, A. K., & Edmonson, J. H. (1994). Pain and its treatment in outpatients with metastatic cancer [Abstract]. The New England Journal of Medicine, 330(9), 592–596.
62. Breitbart, W., Rosenfeld, B. D., Passik, S. D., McDonald, M. V., Thaler, H., & Portenoy, R. K. (1996). The undertreatment of pain in ambulatory AIDS patients [Abstract]. PAIN, 65(2–3), 243–249.
63. Hamberg, K., Risberg, G., Johansson, E. E., & Westman, G. (2002). Gender bias in physicians’ management of neck pain: A study of the answers in a Swedish national examination [Abstract]. Journal of Women’s Health & Gender-Based Medicine, 11(7), 653–666.
64. J. Levine (personal communication, September 21, 2010).
65. Klein, M. M., Downs, H. M., & Oaklander, A. L. (2010, September). Normal innervation in distal-leg skin biopsies: Evidence of superabundance in youth, subsequent axonal pruning, plus new diagnostic recommendations. A Works in Progress paper presented at the 135th Annual Meeting of the American Neurological Association, San Francisco, CA.
66. Racine, M., Tousignant-Laflamme, Y., Kloda, L.A., Dion, D., Dupuis, G., & Choiniere, M. (2012). A systematic literature review of 10 years of research on sex/gender and experimental pain perception—part 2: Do biopsychosocial factors alter pain sensitivity differently in women and men? PAIN, 153(3), 619–635.
67. Lipton, R. B., Stewart, W. F., Diamond, S., Diamond, M. L., & Reed, M. (2001). Prevalence and burden of migraine in the United States: Data from the American migraine study II [Abstract]. Headache: The Journal of Head and Face Pain, 41(7), 646–657.
68. Stewart, W. F., Lipton, R. B., Celentano, D. D., & Reed, M. L. (1992). Prevalence of migraine headache in the United States—relation to age, income, race, and other sociodemographic factors [Abstract]. The Journal of the American Medical Association, 267(1), 64–69.
69. LeResche, L. (1997). Epidemiology of temporomandibular disorders: Implications for the investigation of etiologic factors [Abstract]. Critical Reviews in Oral Biology & Medicine, 8(3), 291–305.
70. LeResche, L., Mancl, L. A., Drangsholt, M. T., Saunders, K., & Korff, M. V. (2005). Relationship of pain and symptoms to pubertal development in adolescents [Abstract]. PAIN, 118(1–2), 201–209.
71. LeResche, L., Mancl, L. A., Drangsholt, M. T., Saunders, K., & Korff, M. V. (2005). Relationship of pain and symptoms to pubertal development in adolescents [Abstract]. PAIN, 118(1–2), 201–209.
72. Cicero, T. J., Nock, B., O’Connor, L., & Meyer, E. R. (2002). Role of steroids in sex differences in morphine-induced analgesia: Activational and organizational effects. Journal of Pharmacology and Experimental Therapeutics, 300(2), 695–670.
73. L. Zeltzer (personal communication, August 31, 2010).
74. W. Maixner (personal communication, February 8, 2012).
75. Ji, Y., Murphy, A. Z., & Traub, R. J. (2003). Estrogen modulates the visceromotor reflex and responses of spinal dorsal horn neurons to colorectal stimulation in the rat [Abstract]. The Journal of Neuroscience, 23(9), 3908–3915.
76. LeResche, L., Saunders, K., Von Korff, M. R., Barlow, W., & Dworkin, S. F. (1997). Use of exogenous hormones and risk of temporomandibular disorder pain [Abstract]. PAIN, 69(1–2), 153–160.
77. LeResche, L., Saunders, K., Von Korff, M. R., Barlow, W., & Dworkin, S. F. (1997). Use of exogenous hormones and risk of temporomandibular disorder pain [Abstract]. PAIN, 69(1–2), 153–160.
78. Musgrave, D. S., Vogt, M. T., Nevitt, M. C., & Cauley, J. A. (2001). Back problems among postmenopausal women taking estrogen replacement therapy: The study of osteoporotic fractures [Abstract]. Spine, 26(14), 1606–1612.
79. Brynhildsen, J. O., Björs, E., Skarsgård, C., & Hammar, M. L. (1998). Is hormone replacement therapy a risk factor for low back pain among postmenopausal women? [Abstract]. Spine, 23(7), 809–813.
80. Fillingim, R. B., & Edwards, R. R. (2001). The association of hormone replacement therapy with experimental pain responses in postmenopausal women. PAIN, 92(1–2), 229–234.
81. Ockene, J. K., Barad, D. H., Cochrane, B. B., Larson, J. C., Gass, M., Wassertheil-Smoller, S., et al. (2005). Symptom experience after discontinuing use of estrogen plus progestin. The Journal of the American Medical Association, 294(2), 183–193.
82. Lichten, E. M., Lichten, J. B., Whitty, A., & Pieper, D. (1996). The confirmation of a biochemical marker for women’s hormonal migraine: The depo-estradiol challenge test [Abstract]. Headache: The Journal of Head and Face Pain, 36(6), 367–371.
83. M. Gold (personal communication, April 25, 2012).
84. Aloisi, A. M., Bachiocco, V., Costantino, A., Stefani, R., Ceccarelli, I., Bertaccini, A., et al. (2007). Cross-sex hormone administration changes pain in transsexual women and men [Abstract]. PAIN, 132(Supplement 1), S60–S67.
85. LeResche, L., Mancl, L., Sherman, J. J., Gandara, B., & Dworkin, S. F. (2003). Changes in temporomandibular pain and other symptoms across the menstrual cycle [Abstract]. PAIN, 106(3), 253–261.
86. F. Cervero (personal communication, September 8, 2010).
87. Fillingim, R. B., & Gear, R. W. (2004). Sex differences in opioid analgesia: Clinical and experimental findings. European Journal of Pain, 8(5), 413–42.
88. Sarton, E., Olofsen, E., Romberg, R., den Hartigh, J., Kest, B., Nieuwenhuijs, D., et al. (2000). Sex differences in morphine analgesia: An experimental study in healthy volunteers [Abstract]. Anesthesiology, 93(5), 1245–1254.
89. Stoffel, E. C., Ulibarri, C. M., Folk, J. E., Rice, K. C., & Craft, R. M. (2005). Gonadal hormone modulation of mu, kappa, and delta opioid antinociception in male and female rats [Abstract]. The Journal of Pain, 6(4), 261–274.
90. Fillingim, R. B., & Gear, R. W. (2004). Sex differences in opioid analgesia: Clinical and experimental findings. European Journal of Pain, 8(5), 413–42.
91. M. Gold (personal communication, April 25, 2012).
92. Fillingim, R. B., & Gear, R. W. (2004). Sex differences in opioid analgesia: Clinical and experimental findings. European Journal of Pain, 8(5), 413–42.
93. Loyd, D. R., Wang, X., & Murphy, A. Z. (2008). Sex differences in μ-opioid receptor expression in the rat midbrain periaqueductal gray are essential for eliciting sex differences in morphine analgesia. The Journal of Neuroscience, 28(52), 14007–14017.
94. Wang, X., Traub, R. J., & Murphy, A. Z. (2006). Persistent pain model reveals sex difference in morphine potency. American Journal of Physiology: Regulatory, Integrative and Comparative Physiology, 291, R300–R306.
95. Society for Neuroscience. (2007, May). Brain briefings: Gender and pain. Retrieved from http://www.sfn.org/siteobjects/published/0000BDF20016F63800FD712C30FA42DD/0000BDF2000006250112C47B47028AD6/file/BrainBriefings_May2007.pdf
96. Cepeda, M. S., & Carr, D. B. (2003). Women experience more pain and require more morphine than men to achieve a similar degree of analgesia. Anesthesia & Analgesia, 97(5), 1464–1468.
97. R. W. Gear (personal communication, September 22, 2010).
98. Niesters, M., Dahan, A., Kest, B., Zacny, J., Stijnen, T., Aarts, L., et al. (2010). Do sex differences exist in opioid analgesia? A systematic review and meta-analysis of human experimental and clinical studies. PAIN, 151(1), 61–68.
99. Niesters, M., Dahan, A., Kest, B., Zacny, J., Stijnen, T., Aarts, L., et al. (2010). Do sex differences exist in opioid analgesia? A systematic review and meta-analysis of human experimental and clinical studies. PAIN, 151(1), 61–68.
100. Niesters, M., Dahan, A., Kest, B., Zacny, J., Stijnen, T., Aarts, L., et al. (2010). Do sex differences exist in opioid analgesia? A systematic review and meta-analysis of human experimental and clinical studies. PAIN, 151(1), 61–68.
101. Niesters, M., Dahan, A., Kest, B., Zacny, J., Stijnen, T., Aarts, L., et al. (2010). Do sex differences exist in opioid analgesia? A systematic review and meta-analysis of human experimental and clinical studies. PAIN, 151(1), 61–68.
102. Miaskowski, C., & Levine, J. D. (1999). Does opioid analgesia show a gender preference for females? Pain Forum, 8(1), 34–44.
103. Gear, R. W., Miaskowski, C., Gordon, N. C., Paul, S. M., Heller, P. H., & Levine, J. D. (1996). Kappa–opioids produce significantly greater analgesia in women than in men [Abstract]. Nature Medicine, 2(11), 1248–1250.
104. Gear, R. W., Gordon, N. C., Heller, P. H., Paul, S., Miaskowski, C., & Levine, J. D. (1996). Gender difference in analgesic response to the kappa-opioid pentazocine [Abstract]. Neuroscience Letters, 205(3), 207–209.
105. Gear, R. W., Miaskowski, C., Gordon, N. C., Paul, S. M., Heller, P. H. & Levine, J. D. (1999). The kappa opioid nalbuphine produces gender- and dose-dependent analgesia and antianalgesia in patients with postoperative pain. PAIN, 83(2), 339–345.
106. J. Mogil (personal communication, April 5, 2012).
107. Mogil, J. S., Wilson, S. G., Chesler, E. J., Rankin, L., Nemmani, K. V. S., Lariviere, W. R., et al. (2003). The melanocortin-1 receptor gene mediates female-specific mechanisms of analgesia in mice and humans. Proceedings of the National Academy of Sciences, 100( 8), 4867–4872.
108. Smith, Y. R., Stohler, C. S., Nichols, T. E., Bueller, J. A., Koeppe, R. A., & Zubieta, J-K. (2006). Pronociceptive and antinociceptive effects of estradiol through endogenous opioid neurotransmission in women [Abstract]. The Journal of Neuroscience, 26(21), 5777–5785.
109. Niesters, M., Dahan, A., Kest, B., Zacny, J., Stijnen, T., Aarts, L., et al. (2010). Do sex differences exist in opioid analgesia? A systematic review and meta-analysis of human experimental and clinical studies. PAIN, 151(1), 61–68.
1. Schechter, N. L., & Allen, D. (1986). Physicians’ attitudes toward pain in children [Abstract]. Journal of Developmental and Behavioral Pediatrics, 7(6), 350–354.
2. Chamberlain, D. B. (1991, May). Babies don’t feel pain: A century of denial in medicine. Paper presented at the Second International Symposium on Circumcision, San Francisco, CA.
3. Swafford, L. I., & Allan, D. (1968). Pain relief in the pediatric patient. Medical Clinics of North America, 52(1), 133.
4. N. Schechter (personal communication, December 3, 2010).
5. C. Berde (personal communication, December 3, 2010).
6. J. Lawson (personal communication, December 2, 2010).
7. Lawson, J. R. (1988). Standards of practice and the pain of premature infants. Zero to Three/The Bulletin of the National Center for Clinical Infant Programs, 9(2), 1–5.
8. Eland, J. M., & Anderson, M. J. (1977). The experience of pain in children. In A. Jacox (Ed.), Pain: A sourcebook for nurses and other health professionals (pp. 453–476). Boston: Little, Brown, & Company.
9. Asprey, J. R. (1994). Postoperative analgesic prescription and administration in a pediatric population [Abstract]. Journal of Pediatric Nursing, 9(3), 150–157.
10. Perry, S., & Heidrich, G. (1982). Management of pain during debridement: A survey of US burn units [Abstract]. PAIN, 13(3), 267–280.
11. Beyer, J. E., DeGood, D. E., Ashley, L. C., & Russell, G. A. (1983). Patterns of postoperative analgesic use with adults and children following cardiac surgery [Abstract]. PAIN, 17(1), 71–81.
12. Mather, L., & Mackie, J. (1983). The incidence of postoperative pain in children [Abstract]. PAIN, 15(3), 271–282.
13. Schechter, N. L., Allen, D. A., & Hanson, K. (1986). Status of pediatric pain control: A comparison of hospital analgesic usage in children and adults [Abstract]. Pediatrics, 77(1), 11–15.
14. Fitzgerald, M., & Beggs, S. (2001). The neurobiology of pain: Developmental aspects [Abstract]. The Neuroscientist, 7(3), 246–257.
15. Fitzgerald, M., Millard, C., & McIntosh, N. (1989). Cutaneous hypersensitivity following peripheral tissue damage in newborn infants and its reversal with topical anaesthesia [Abstract]. PAIN, 39(1), 31–36.
16. Slater, R., Fabrizi, L., Worley, A., Meek, J., Boyd, S., & Fitzgerald, M. (2010). Premature infants display increased noxious-evoked neuronal activity in the brain compared to healthy age-matched term-born infants [Abstract]. NeuroImage, 52(2), 583–589.
17. Slater, R., Worley, A., Fabrizi, L., Roberts, S., Meek, J., Boyd, S., et al. (2010). Evoked potentials generated by noxious stimulation in the human infant brain [Abstract]. European Journal of Pain, 14(3), 321–326.
18. Andrews, K., & Fitzgerald, M. (1994). The cutaneous withdrawal reflex in human neonates: Sensitization, receptive fields, and the effects of contralateral stimulation [Abstract]. PAIN, 56(1), 95–101.
19. Fitzgerald, M., & Jennings, E. (1999). The postnatal development of spinal sensory processing. Proceedings of the National Academy of Sciences, 96(14), 7719–7722.
20. Marsh, D., Dickenson, A., Hatch, D., & Fitzgerald, M. (1999). Epidural opioid analgesia in infant rats II: Responses to carrageenan and capsaicin. PAIN, 82(1), 33–38.
21. Fitzgerald, M. (1991). Development of pain mechanisms. British Medical Bulletin, 47(3), 667–675.
22. Fitzgerald, M., & Walker, S. M. (2009). Infant pain management: A developmental neurobiological approach. Nature Clinical Practice: Neurology, 5(1), 35–50.
23. Anand, K. J. S., & Hickey, P. R. (1987). Pain and its effects in the human neonate and fetus. New England Journal of Medicine, 317(21), 1323.
24. Anand, K. J. S. (2001). Consensus statement for the prevention and management of pain in the newborn [Abstract]. Archives of Pediatrics and Adolescent Medicine, 155(2), 173–180.
25. Anand, K. J. S. (1998). Clinical importance of pain and stress in preterm neonates [Abstract]. Biology of the Neonate, 73(1), 1–9.
26. Anand, K. J., & Carr, D. B. (1989). The neuroanatomy, neurophysiology, and neurochemistry of pain, stress, and analgesia in newborns and children [Abstract]. Pediatric Clinics of North America, 36(4), 795–822.
27. Anand, K., Hall, R., Desai, N., Shephard, B., Bergqvist, L. L., Young, T. E., et al. (2004). Effects of morphine analgesia in ventilated preterm neonates: Primary outcomes from the NEOPAIN randomised trial. The Lancet, 363(9422), 1673–1682.
28. Anand, K. J. S., Aranda, J. V., Berde, C. B., Buckman, S. A., Capparelli, E. V., Carlo, W., et al. (2006). Summary proceedings from the neonatal pain-control group [Abstract]. Pediatrics, 117(3), S9–S22.
29. Anand, K., Johnston, C. C., Oberlander, T. F., Taddio, A., Tutag Lehr, V., & Walco, G. A. (2005). Analgesia and local anesthesia during invasive procedures in the neonate [Abstract]. Clinical Therapeutics, 27(6), 844–876.
30. Carbajal, R., & Anand, K. (2008). Prevention of pain in neonates [Reply]. The Journal of the American Medical Association, 300(19), 2248–2249.
31. Fabrizi, L., Slater, R., Worley, A., Meek, J., Boyd, S., Olhede, S., & Fitzgerald, M. (2011). A shift in sensory processing that enables the developing human brain to discriminate touch from pain. Current Biology, 21(18), 1552–1558.
32. Johnston, C. (2010). From the mouths of babes: What have we learned from studies of pain in neonates? Paper presented at the International Association of Pain’s 13th World Congress on Pain, Montreal, Canada.
33. Fitzgerald, M., & Koltzenburg, M. (1986). The functional development of descending inhibitory pathways in the dorsolateral funiculus of the newborn rat spinal cord [Abstract]. Developmental Brain Research, 24(1–2), 261–270.
34. Anand, K. J. S., & Hickey, P. R. (1987). Pain and its effects in the human neonate and fetus. New England Journal of Medicine, 317(21), 1321–1329.
35. Csontos, K., Rust, M., Hollt, V., Mahr, W., Kromer, W., & Teschemacher, H. J. (1979). Elevated plasma beta-endorphin levels in pregnant women and their neonates. Life Sciences, 25(10), 835–844.
36. Gautray, J. P., Jolivet, A., Viehl, J. P., & Guillemin, R. (1977). Presence of immunoassayable beta-endorphin in human amniotic fluid: Elevation in cases of fetal distress. American Journal of Obstetrics and Gynecology, 129(2), 211–212.
37. Emde, R. N, Harmon, R. J., Metcalf, D., Koenig, K. L., & Wagonfeld, S. (1971). Stress and neonatal sleep [Abstract]. Psychosomatic Medicine, 33(6), 491–497.
38. Talbert, L. M., Kraybill, E. N., & Potter, H. D. (1976). Adrenal cortical response to circumcision in the neonate [Abstract]. Obstetrics and Gynecology, 48(2), 208–210.
39. Williamson, P. S., & Williamson, M. L. (1983). Physiologic stress reduction by a local anesthetic during newborn circumcision. Pediatrics, 71(1), 36–40.
40. Taddio, A., Katz, J., Ilersich, A. L., & Koren, G. (1997). Effect of neonatal circumcision on pain response during subsequent routine vaccination [Abstract]. The Lancet, 349(9052), 599–603.
41. Taddio, A., Stevens, B., Craig, K., Rastogi, P., Ben-David, S., Shennan, A., et al. (1997). Efficacy and safety of lidocaine–prilocaine cream for pain during circumcision [Abstract]. New England Journal of Medicine, 336(17), 1197–1201.
42. Weisman, S. J., Bernstein, B., & Schechter, N. L. (1998). Consequences of inadequate analgesia during painful procedures in children [Abstract]. Archives of Pediatrics and Adolescent Medicine, 152(2), 147–149.
43. Zeltzer, L. K., & Krane, E. J. (2011). Pediatric pain management. In R. M. Kliegman, R. E. Behrmen, B. F. Stanton, N. Schor, & J. St. Geme (Eds.), Nelson’s textbook of pediatrics (19th ed., p. 7). New York: Elsevier.
44. Anand, K. J., Sippell, W. G., & Aynsley-Green, A. (1987). Randomised trial of fentanyl anaesthesia in preterm babies undergoing surgery: Effects on the stress response. [Abstract]. The Lancet, 1(8524), 62–66.
45. Anand, K. J. S., Carr, D. B., & Mickey, P. R. (1987). Randomised trial of high-dose sufentanil anesthesia in neonates undergoing cardiac surgery: Hormonal and hemodynamic stress responses [Abstract]. Anesthesiology, 67(3), A501.
46. Berde, C. B., & Sethna, N. F. (2002). Analgesics for the treatment of pain in children. New England Journal of Medicine, 347(14), 1094–1103.
47. Cohen, M. M., Cameron, C. B., & Duncan, P. G. (1990). Pediatric anesthesia morbidity and mortality in the perioperative period [Abstract]. Anesthesia & Analgesia, 70(2), 160–167.
48. Zeltzer, L. K., & Krane, E. J. (2011). Pediatric pain management. In R. M. Kliegman, R. E. Behrmen, B. F. Stanton, N. Schor, & J. St. Geme (Eds.), Nelson’s textbook of pediatrics (19th ed., p. 5). New York: Elsevier.
49. Berde, C. B., & Sethna, N. F. (2002). Analgesics for the treatment of pain in children. New England Journal of Medicine, 347(14), 1094–1103.
50. Anand, K. J. S., & Arnold, J. H. (1994). Opioid tolerance and dependence in infants and children [Abstract]. Critical Care Medicine, 22(2), 334–342.
51. Suresh, S., & Anand, K. J. S. (1998). Opioid tolerance in neonates: Mechanisms, diagnosis, assessment, and management [Abstract]. Seminars in Perinatology, 22(5), 425–433.
52. Berde, C. B., Lehn, B. M., Yee, J. D., Sethna, N. F., & Russo, D. (1991). Patient-controlled analgesia in children and adolescents: A randomized, prospective comparison with intramuscular administration of morphine for postoperative analgesia [Abstract]. The Journal of Pediatrics, 118(3), 460–466.
53. Berde, C. B., Lehn, B. M., Yee, J. D., Sethna, N. F., & Russo, D. (1991). Patient-controlled analgesia in children and adolescents: A randomized, prospective comparison with intramuscular administration of morphine for postoperative analgesia [Abstract]. The Journal of Pediatrics, 118(3), 460–466.
54. Zeltzer, L. K., & Krane, E. J. (2011). Pediatric pain management. In R. M. Kliegman, R. E. Behrmen, B. F. Stanton, N. Schor, & J. St. Geme (Eds.), Nelson’s textbook of pediatrics (19th ed., p. 8). New York: Elsevier.
55. Zeltzer, L. K., & Krane, E. J. (2011). Pediatric pain management. In R. M. Kliegman, R. E. Behrmen, B. F. Stanton, N. Schor, & J. St. Geme (Eds.), Nelson’s textbook of pediatrics (19th ed., p. 8). New York: Elsevier.
56. Johnston, C. (2010). From the mouths of babes: What have we learned from studies of pain in neonates? Paper presented at the International Association of Pain’s 13th World Congress on Pain, Montreal, Canada.
57. Barr, R. G., Pantel, M. S., Young, S. N., Wright, J. H., Hendricks, L. A., & Gravel, R. (1999). The response of crying newborns to sucrose: Is it a “sweetness” effect? Physiology & Behavior, 66(3), 409–417.
58. Stevens, B., Yamada, J., & Ohlsson, A. (2010). Sucrose for analgesia in newborn infants undergoing painful procedures [Review]. Cochrane Database of Systematic Reviews, 2010(1), CD001069.
59. Akman, I. (2002). Sweet solutions and pacifiers for pain relief in newborn infants [Abstract]. The Journal of Pain, 3(3), 199–202.
60. Barr, R. G., Young, S. N., Wright, J. H., Gravel, R., & Alkawaf, R. (1999). Differential calming responses to sucrose taste in crying infants with and without colic [Abstract]. Pediatrics, 103(5), e68.
61. Johnston, C. (2010). From the mouths of babes: What have we learned from studies of pain in neonates? Paper presented at the International Association of Pain’s 13th World Congress on Pain, Montreal, Canada.
62. Slater, R., Cornelissen, L., Fabrizi, L., Patten, D., Yoxen, J., Worley, A., et al. (2010). Oral sucrose as an analgesic drug for procedural pain in newborn infants: A randomised controlled trial [Abstract]. The Lancet, 376(9748), 1225–1232.
63. Johnston, C. (2010). From the mouths of babes: What have we learned from studies of pain in neonates? Paper presented at the International Association of Pain’s 13th World Congress on Pain, Montreal, Canada.
64. Carbajal, R., Chauvet, X., Couderc, S., & Olivier-Martin, M. (1999). Randomised trial of analgesic effects of sucrose, glucose, and pacifiers in term neonates. British Medical Journal, 319(7222), 1393–1397.
65. Gray, L., Miller, L. W., Philipp, B. L., & Blass, E. M. (2002). Breastfeeding is analgesic in healthy newborns [Abstract]. Pediatrics, 109(4), 590–593.
66. Carbajal, R., Veerapen, S., Couderc, S., Jugie, M., & Ville, Y. (2003). Analgesic effect of breast feeding in term neonates: Randomised controlled trial. British Medical Journal, 326(7379), 1–5.
67. Johnston, C. C., Filion, F., Campbell-Yeo, M., Goulet, C., Bell, L., McNaughton, K., et al. (2009). Enhanced kangaroo mother care for heel lance in preterm neonates: A crossover trial [Abstract]. Journal of Perinatology, 29(1), 51–56.
68. Johnston, C. C., Filion, F., Campbell-Yeo, M., Goulet, C., Bell, L., McNaughton, K., et al. (2008). Kangaroo mother care diminishes pain from heel lance in very preterm neonates: A crossover trial. BMC Pediatrics, 8(1), 13.
69. Gray, L., Watt, L., & Blass, E. M. (2000). Skin-to-skin contact is analgesic in healthy newborns [Abstract]. Pediatrics, 105(1), e14.
70. Johnston, C. C., Abbott, F. V., Gray-Donald, K., & Jeans, M. E. (1992). A survey of pain in hospitalized patients aged 4–14 years [Abstract]. The Clinical Journal of Pain, 8(2), 154–163.
71. Jacob, E., & Puntillo, K. A. (2000). Variability of analgesic practices for hospitalized children on different pediatric specialty units [Abstract]. Journal of Pain and Symptom Management, 20(1), 59–67.
72. Ellis, J. A., O’Connor, B. V., Cappelli, M., Goodman, J. T., Blouin, R., & Reid, C. W. (2002). Pain in hospitalized pediatric patients: How are we doing? [Abstract]. The Clinical Journal of Pain, 18(4), 262–269.
73. Karling, M., RenströNewm, M., & Ljungman, G. (2002). Acute and postoperative pain in children: A Swedish nationwide survey [Abstract]. Acta Paediatrica, 91(6), 660–666.
74. Alexander, J., & Manno, M. (2003). Underuse of analgesia in very young pediatric patients with isolated painful injuries [Abstract]. Annals of Emergency Medicine, 41(5), 617–622.
75. Simons, S. H. P., van Dijk, M., Anand, K. S., Rooft hooft, D., van Lingen, R. A., & Tibboel, D. (2003). Do we still hurt newborn babies? A prospective study of procedural pain and analgesia in neonates [Abstract]. Archives of Pediatrics and Adolescent Medicine, 157(11), 1058–1064.
76. Carbajal, R., Rousset, A., Danan, C., Coquery, S., Nolent, P., Ducrocq, S., et al. (2008). Epidemiology and treatment of painful procedures in neonates in intensive care units. The Journal of the American Medical Association, 300(1), 60–70.
77. Carbajal, R., Nguyen-Bourgain, C., & Armengaud, J. B. (2008). How can we improve pain relief in neonates? Expert Review of Neurotherapeutics, 8(11), 1617–1620.
78. Taylor, E. M., Boyer, K., & Campbell, F. A. (2008). Pain in hospitalized children: A prospective cross-sectional survey of pain prevalence, intensity, assessment and management in a Canadian pediatric teaching hospital. Pain Research & Management: The Journal of the Canadian Pain Society, 13(1), 25–32.
79. Harrison, D., Loughnan, P., & Johnston, L. (2006). Pain assessment and procedural pain management practices in neonatal units in Australia [Abstract]. Journal of Paediatrics and Child Health, 42(1-2), 6–9.
80. N. Schechter (personal communication, December 3, 2010).
81. Schechter, N. L., Allen, D. A., & Hanson, K. (1986). Status of pediatric pain control: A comparison of hospital analgesic usage in children and adults [Abstract]. Pediatrics, 77(1), 11–15.
82. Schechter, N. L., Zempsky, W. T., Cohen, L. L., McGrath, P. J., McMurtry, C. M., & Bright, N. S. (2007). Pain reduction during pediatric immunizations: Evidence-based review and recommendations. Pediatrics, 119(5), e1184–e1198.
83. Schechter, N. L., Bernstein, B. A., Zempsky, W. T., Bright, N. S., & Willard, A. K. (2010). Educational outreach to reduce immunization pain in office settings. Pediatrics, 126(6), e1514–e1521.
84. Schechter, N. L. (1989). The undertreatment of pain in children: An overview. Pediatric Clinics of North America, 36(4), 781–794.
85. Schechter, N. L. (2008). From the ouchless place to comfort central: The evolution of a concept. Pediatrics, 122(Supplement 3), S154–S160.
86. Harrison, D., Loughnan, P., & Johnston, L. (2006). Pain assessment and procedural pain management practices in neonatal units in Australia [Abstract]. Journal of Paediatrics and Child Health, 42(1-2), 6–9.
87. Wolfe, J., Grier, H. E., Klar, N., Levin, S. B., Ellenbogen, J. M., Salem-Schatz, S., et al. (2000). Symptoms and suffering at the end of life in children with cancer [Abstract]. New England Journal of Medicine, 342(5), 326–333.
88. Wolfe, J., Hammel, J. F., Edwards, K. E., Duncan, J., Comeau, M., Breyer, J., et al. (2008). Easing of suffering in children with cancer at the end of life: Is care changing? Journal of Clinical Oncology, 26(10), 1717–1723.
89. Schechter, N. L., Finley, G. A., Bright, N. S., Laycock, M., & Forgeron, P. (2010). ChildKind: A global initiative to reduce pain in children. Pediatric Pain Letter, 12(3), 26–30.
90. J. Lawson (personal communication, December 2, 2010.)
1. Taylor, J. B. (2008). My stroke of insight: A brain scientist’s personal journey (p. 17). New York: Viking.
2. Beecher, H. K. (1956). Relationship of significance of wound to pain experienced [Abstract]. Journal of the American Medical Association, 161(17), 1609–1613.
3. Wiech, K., Lin, C-S., Brodersen, K. H., Bingel, U., Ploner, M., & Tracey, I. (2010). Anterior insula integrates information about salience into perceptual decisions about pain. Journal of Neuroscience, 30(48), 16324–16331.
4. Lester, N., & Keefe, F. (1997). Coping with chronic pain. In A. Baum, S. Newman, J. Weinman, R. West, & C. McManus (Eds.), Cambridge handbook of psychology, health and medicine (pp. 87–90). Cambridge, UK: Cambridge University Press.
5. Keefe, F. J., Rumble, M. E., Scipio, C. D., Giordano, L. A., & Perri, L. C. M. (2004). Psychological aspects of persistent pain: Current state of the science. The Journal of Pain, 5(4), 195–211.
6. Institute of Medicine, Committee on Advancing Pain Research, Care, and Education. (2011). Relieving pain in America: A blueprint for transforming prevention, care, education and research (pp. 3–17). Prepublication copy. Washington, DC: National Academies Press.
7. van Middendorp, H., Lumley, M. A., Jacobs, J. W. G., Bijlsma, J. W. J., & Geenen, R. (2010). The effects of anger and sadness on clinical pain reports and experimentally-induced pain thresholds in women with and without fibromyalgia [Abstract]. Arthritis Care & Research, 62(10), 1370–1376.
8. Younger, J., Aron, A., Parke, S., Chatterjee, N., & Mackey, S., (2010). Viewing pictures of a romantic partner reduces experimental pain: Involvement of neural reward systems. PloS One, 5(10), e13309.
9. Reese, J. B., Somers, T. J., Keefe, F. J., Mosley-Williams, A., & Lumley, M. A. (2010). Pain and functioning of rheumatoid arthritis patients based on marital status: Is a distressed marriage preferable to no marriage? [Abstract]. The Journal of Pain, 11(10), 958–964.
10. Wasan, A. D., Sullivan, M. D., & Clark, M. R. (2010). Psychiatric illness, depression, anxiety, and somatoform pain disorders. In J. C. Ballantyne, J. P. Rathmell, and S. M. Fishman (Eds.), Bonica’s management of pain (4th ed., pp. 393–417). Philadelphia: Lippincott, Williams, and Wilkins.
11. F. Keefe (personal communication, January 3, 2011.)
12. Engel, G. L. (1977). The need for a new medical model: A challenge for biomedicine. Science, 196(4286), 129–136.
13. Lumley, M. A., Cohen, J. L., Borszcz, G. S., Cano, A., Radcliffe, A. M., Porter, L. S., et al. (2011). Pain and emotion: A biopsychosocial review of recent research. Journal of Clinical Psychology, 67(9), 942–968.
14. Cole, S. W., Hawkley, L. C., Arevalo, J. M. G., & Cacioppo, J. T. (2011). Transcript origin analysis identifies antigen-presenting cells as primary targets of socially regulated gene expression in leukocytes. Proceedings of the National Academy of Sciences, 108(7), 3080–3085.
15. Narayan, M. C. (2010). Culture’s effects on pain assessment and management. The American Journal of Nursing, 110(4), 38–47.
16. P. Cowan (personal communication, Oct. 18, 2010).
17. Foreman, J. (2006, February 6). Trick or treatment? The Boston Globe, p. C1.
18. Foreman, J. (2006, February 6). Trick or treatment? The Boston Globe, p. C1.
19. Benedetti, F., Mayberg, H. S., Wager, T. D., Stohler, C. S., & Zubieta, J-K. (2005). Neurobiological mechanisms of the placebo effect. Journal of Neuroscience, 25(45), 10390–10402.
20. Finniss, D. G., Kaptchuk, T. J., Miller, F., & Benedetti, F. (2010). Biological, clinical, and ethical advances of placebo effects. The Lancet, 375(9715), 686–695.
21. Jamison, R. N. (2011). Nonspecific treatment effects in pain medicine. PAIN: Clinical Updates, 19(2), 1–7.
22. Grelotti, D. J., & Kaptchuk, T. J. (2011). Placebo by proxy. British Medical Journal, 343, d4345.
23. T. Kaptchuk (personal communication, April 4, 2012).
24. Kong, J., Kaptchuk, T. J., Polich, G., Kirsch, I., & Gollub, R. L. (2007). Placebo analgesia: Findings from brain imaging studies and emerging hypotheses. Reviews in the Neurosciences, 18(3–4), 173–190.
25. Hrobjartsson, A., & Gotzsche, P. C. (2010). Placebo interventions for all clinical conditions. Cochrane Database of Systematic Reviews , 2010(1), CD003974.
26. Kaptchuk, T. J., Friedlander, E., Kelley, J. M., Sanchez, M. N., Kokkotou, E., Singer, J. P., et al. (2010). Placebos without deception: A randomized controlled trial in irritable bowel syndrome. PloS One, 5(12), e15591.
27. T. Kaptchuk (personal communication, December 29, 2010).
28. Finniss, D. G., Kaptchuk, T. J., Miller, F., & Benedetti, F. (2010). Biological, clinical, and ethical advances of placebo effects. The Lancet, 375(9715), 686–695.
29. Jensen, K. B., Kaptchuk, T. J., Kirsch, I., Lindstrom, K. M., Berna, C., Gollub, R. L., et al, (2012) Nonconscious activation of placebo and nocebo pain responses. Proceedings of the National Academy of Sciences, 109(39), 15959–15964.
30. Kong, J., Kaptchuk, T. J., Polich, G., Kirsch, I., & Gollub, R. L. (2007). Placebo analgesia: Findings from brain imaging studies and emerging hypotheses. Reviews in the Neurosciences, 18(3–4), 173–190.
31. Bingel, U., Wanigasekera, V., Wiech, K., Ni Mhuircheartaigh, R., Lee, M. C., Ploner, M., et al. (2011). The effect of treatment expectation on drug efficacy: Imaging the analgesic benefit of the opioid remifentanil [Abstract]. Science Translational Medicine, 3(70), 70ra14.
32. Gollub, R. L., & Kong, J. (2011). For placebo effects in medicine, seeing is believing [Abstract]. Science Translational Medicine, 3(70), 70ps5.
33. Wager, T. D., Rilling, J. K., Smith, E. E., Sokolik, A., Casey, K. L., Davidson, R. J., et al. (2004). Placebo-induced changes in fMRI in the anticipation and experience of pain [Abstract]. Science, 303(5661), 1162–1167.
34. Price, D. D., Craggs, J., Verne, G. N., Perlstein, W. M., & Robinson, M. E. (2007). Placebo analgesia is accompanied by large reductions in pain-related activity in irritable bowel syndrome patients [Abstract]. PAIN, 127(1), 63–72.
35. Koyama, T., McHaffie, J. G., Laurienti, P. J., & Coghill, R. C. (2005). The subjective experience of pain: Where expectations become reality [Abstract]. Proceedings of the National Academy of Sciences, 102(36), 12950–12955.
36. Porro, C. A., Baraldi, P., Pagnoni, G., Serafini, M., Facchin, P., Maieron, M., et al. (2002). Does anticipation of pain affect cortical nociceptive systems? [Abstract]. The Journal of Neuroscience, 22(8), 3206–3214.
37. R. Gollub (personal communication, January 5, 2011).
38. Levine, J. D., Gordon, N. C., & Fields, H. L. (1978). The mechanism of placebo analgesia. The Lancet, 312(8091), 654–657.
39. Petrovic, P., Kalso, E., Petersson, K. M., & Ingvar, M. (2002). Placebo and opioid analgesia—imaging a shared neuronal network [Abstract]. Science, 295(5560), 1737–1740.
40. Zubieta, J-K., Bueller, J. A., Jackson, L. R., Scott, D. J., Xu, Y., Koeppe, R. A., et al. (2005). Placebo effects mediated by endogenous opioid activity on μ-opioid receptors [Abstract]. Journal of Neuroscience, 25(34), 7754–7762.
41. Wager, T. D., Scott, D. J., & Zubieta, J-K. (2007). Placebo effects on human μ-opioid activity during pain. Proceedings of the National Academy of Sciences, 104(26), 11056–11061.
42. Zubieta, J-K., Yau, W. Y., Scott, D. J., & Stohler, C. S. (2006). Belief or need? Accounting for individual variations in the neurochemistry of the placebo effect [Abstract]. Brain, Behavior, and Immunity, 20(1), 15–26.
43. Benedetti, F., Arduino, C., & Amanzio, M. (1999). Somatotopic activation of opioid systems by target-directed expectations of analgesia [Abstract]. The Journal of Neuroscience, 19(9), 3639–3648.
44. Benedetti, F., Arduino, C., & Amanzio, M. (1999). Somatotopic activation of opioid systems by target-directed expectations of analgesia [Abstract]. The Journal of Neuroscience, 19(9), 3639–3648.
45. Pollo, A., Vighetti, S., Rainero, I., & Benedetti, F. (2003). Placebo analgesia and the heart. PAIN, 102(1), 125–133.
46. Benedetti, F., Amanzio, M., Rosato, R., & Blanchard, C. (2011). Nonopioid placebo analgesia is mediated by CB1 cannabinoid receptors. Nature Medicine, 17(10), 1228–1230.
47. Talkington, M. (2011, October). Endocannabinoids pitch in for placebo effect. Retrieved from http://www.painresearchforum.org/news/10072-endocannabinoids-pitch-placebo-effect?search_term=Endocannabinoids%2
48. Pollo, A., Vighetti, S., Rainero, I., & Benedetti, F. (2003). Placebo analgesia and the heart. PAIN, 102(1–2), 125–133.
49. T. Kaptchuk (personal communication, February 18, 2011).
50. Ohayon, M. M., & Schatzberg, A. F. (2003). Using chronic pain to predict depressive morbidity in the general population. Archives of General Psychiatry, 60(1), 39–47.
51. Elman, I., Zubieta, J-K., & Borsook, D. (2011). The missing P in psychiatric training: Why it is important to teach pain to psychiatrists. Archives of General Psychiatry, 68(1), 12–20.
52. A. Wasan (personal communication, January 3, 2011).
53. Kroenke, K., Spitzer, R. L., Williams, J. B. W., Linzer, M., Hahn, S. R., deGruy, F. V., III, et al. (1994). Physical symptoms in primary care: Predictors of psychiatric disorders and functional impairment. Archives of Family Medicine, 3(9), 774.
54. Wasan, A. D., Sullivan, M. D., & Clark, M. R. (2010). Psychiatric illness, depression, anxiety, and somatoform pain disorders. In J. C. Ballantyne, J. P. Rathmell, and S. M. Fishman, (Eds.), Bonica’s management of pain (4th ed., pp. 393–417). Philadelphia: Lippincott, Williams, and Wilkins.
55. Berna, C., Leknes, S., Holmes, E. A., Edwards, R. R., Goodwin, G. M., & Tracey, I. (2010). Induction of depressed mood disrupts emotion regulation neurocircuitry and enhances pain unpleasantness. Biological Psychiatry, 67(11), 1083–1090.
56. R. Jamison (personal communication, December 20, 2010).
57. Dersh, J., Mayer, T., Theodore, B. R., Polatin, P., & Gatchel, R. J. (2007). Do psychiatric disorders first appear preinjury or postinjury in chronic disabling occupational spinal disorders? [Abstract]. Spine, 32(9), 1045–1051.
58. The American Academy of Neurology. (2012). Migraine linked to increased risk of depression in women [Press release]. Retrieved from http://www.aan.com/press/?fuseaction=release.view&release=1033
59. Wasan, A. D., Sullivan, M. D., & Clark, M. R. (2010). Psychiatric illness, depression, anxiety, and somatoform pain disorders. In J. C. Ballantyne, J. P. Rathmell, and S. M. Fishman (Eds.), Bonica’s management of pain (4th ed., pp. 393–417). Philadelphia: Lippincott, Williams, and Wilkins.
60. R. Jamison (personal communication, December 30, 2010).
61. Wasan, A. D., Sullivan, M. D., & Clark, M. R. (2010). Psychiatric illness, depression, anxiety, and somatoform pain disorders. In J. C. Ballantyne, J. P. Rathmell, and S. M. Fishman (Eds.), Bonica’s management of pain (4th ed., pp. 393–417). Philadelphia: Lippincott, Williams, and Wilkins.
62. Wasan, A. D., Davar, G., & Jamison, R. (2005). The association between negative affect and opioid analgesia in patients with discogenic low back pain [Abstract]. PAIN, 117(3), 450–461.
63. Kroenke, K. (2005). Somatic symptoms and depression: A double hurt. Primary Care Companion to the Journal of Clinical Psychiatry, 7(4), 148–149.
64. Kroenke, K. (2003). The interface between physical and psychological symptoms. The Primary Care Companion to the Journal of Clinical Psychiatry, 5(Supplement 7), 11–18.
65. K. Kroenke (personal communication, December 30, 2010).
66. Giesecke, T., Gracely, R. H., Williams, D. A., Geisser, M. E., Petzke, F. W., & Clauw, D. J. (2005). The relationship between depression, clinical pain, and experimental pain in a chronic pain cohort. Arthritis & Rheumatism, 52(5), 1577–1584.
67. Meier, B. (2003). Pain killer: A “wonder” drug’s trail of addiction and death. Emmaus, PA: Rodale Books.
68. Wasan, A. D., Sullivan, M. D., & Clark, M. R. (2010). Psychiatric illness, depression, anxiety, and somatoform pain disorders. In J. C. Ballantyne, J. P. Rathmell, and S. M. Fishman (Eds.), Bonica’s management of pain (4th ed., pp. 393–417). Philadelphia: Lippincott, Williams, and Wilkins.
69. Bair, M. J., Robinson, R. L., Katon, W., & Kroenke, K. (2003). Depression and pain comorbidity: A literature review. Archives of Internal Medicine, 163(20), 2433–2445.
70. Urquhart, D. M., Hoving, J. L., Assendelft, W. J. J., Roland, M., & van Tulder, M. W. (2008). Antidepressants for non-specific low back pain. Cochrane Database of Systematic Reviews, 2008(1), CD001703.
71. Seidel, S., Aigner, M., Ossege, M., Pernicka, E., Wildner, B., & Sycha, T. (2010). Antipsychotics for acute and chronic pain in adults [Abstract]. Journal of Pain and Symptom Management, 39(4), 768–778.
72. Urquhart, D. M., Hoving, J. L., Assendelft, W. J. J., Roland, M., & van Tulder, M. W. (2008). Antidepressants for non-specific low back pain. Cochrane Database of Systematic Reviews, 2008(1), CD001703.
73. Lunn, M. P., Hughes, R. A., & Wiffen, P. J. (2009). Duloxetine for treating painful neuropathy or chronic pain [Abstract]. Cochrane Database of Systematic Reviews, 2009(4), CD007115.
74. Saarto, T., & Wiffen, P. J. (2005). Antidepressants for neuropathic pain [Abstract]. Cochrane Database of Systematic Reviews, 2005(3), CD005454.
75. Jackson, J. L., O Malley, P. G., & Kroenke, K. (2006). Antidepressants and cognitive-behavioral therapy for symptom syndromes. CNS Spectrums, 11(3), 212–222.
76. Kroenke, K., Bair, M. J., Damush, T. M., Wu, J., Hoke, S., Sutherland, J., et al. (2009). Optimized antidepressant therapy and pain self-management in primary care patients with depression and musculoskeletal pain. The Journal of the American Medical Association, 301(20), 2099–2110.
77. L. Zeltzer (personal communication, August 31, 2010).
78. Keefe, F. J., Lefebvre, J. C., Egert, J. R., Affleck, G., Sullivan, M. J., & Caldwell, D. S. (2000). The relationship of gender to pain, pain behavior, and disability in osteoarthritis patients: The role of catastrophizing. PAIN, 87(3), 325–334.
79. Edwards, R. R., Haythornthwaite, J. A., Sullivan, M. J., & Fillingim, R. B. (2004). Catastrophizing as a mediator of sex differences in pain: Differential effects for daily pain versus laboratory-induced pain. PAIN, 111(3), 335–341.
80. R. Portenoy (personal communication, September 10, 2009).
81. Sullivan, M. J. L., Bishop, S. R., & Pivik, J. (1995). The pain catastrophizing scale: Development and validation. Psychological Assessment, 7(4), 524–532.
82. Edwards, R. R., Bingham, C.O., III, Bathon, J., & Haythornthwaite, J. A. (2006). Catastrophizing and pain in arthritis, fibromyalgia, and other rheumatic diseases. Arthritis Care & Research, 55(2), 325–332.
83. Edwards, R. R., Kronfli, T., Haythornthwaite, J. A., Smith, M. T., McGuire, L., & Page, G. G. (2008). Association of catastrophizing with interleukin-6 responses to acute pain. PAIN, 140(1), 135–144.
84. Gracely, R. H., Geisser, M. E., Giesecke, T., Grant, M. A. B., Petzke, F., Williams, D. A., et al. (2004). Pain catastrophizing and neural responses to pain among persons with fibromyalgia [Abstract]. Brain, 127(4), 835–843.
85. Seminowicz, D. A., & Davis, K. D. (2006). Cortical responses to pain in healthy individuals depends on pain catastrophizing. PAIN, 120(3), 297–306.
86. Superio-Cabuslay, E., Ward, M. M., & Lorig, K. R. (1996). Patient education interventions in osteoarthritis and rheumatoid arthritis: A meta-analytic comparison with nonsteroidal anti-inflammatory drug treatment [Abstract]. Arthritis & Rheumatism, 9(4), 292–301.
87. Keefe, F. J., Abernethy, A. P., & Campbell, L. C. (2005). Psychological approaches to understanding and treating disease-related pain. Annual Review of Psychology, 56, 601–630.
88. Keefe, F. J., Caldwell, D. S., Williams, D. A., Gil, K. M., Mitchell, D., Robertson, C., et al. (1991). Pain coping skills training in the management of osteoarthritic knee pain: A comparative study. Behavior Therapy, 21(1), 49–62.
89. Benson, H., & Klipper, M. Z. (2000). The relaxation response. New York: HarperCollins.
90. Keefe, F. J., Rumble, M. E., Scipio, C. D., Giordano, L. A., & Perri, L. C. M. (2004). Psychological aspects of persistent pain: Current state of the science. The Journal of Pain, 5(4), 195–211.
91. Chou, R., & Huffman, L. (2007). Nonpharmacologic therapies for acute and chronic low back pain: A review of the evidence for an American Pain Society/American College of Physicians clinical practice guideline. Annals of Internal Medicine, 147(7), 492–504.
92. Gatchel, R. J., & Rollings, K. H. (2008). Evidence-informed management of chronic low back pain with cognitive behavioral therapy. The Spine Journal, 8, 40–44.
93. Burns, D. D. (1999). Feeling good: The new mood therapy. New York: Harper Paperbacks.
94. Keefe, F. J., Abernethy, A. P., & Campbell, L. C. (2005). Psychological approaches to understanding and treating disease-related pain. Annual Review of Psychology, 56, 601–630.
95. Turner, J. A., Mancl, L., & Aaron, L. A. (2006). Short-and long-term efficacy of brief cognitive-behavioral therapy for patients with chronic temporomandibular disorder pain: A randomized, controlled trial [Abstract]. PAIN, 121(3), 181–194.
96. Jackson, J. L., O’Malley, P. G., & Kroenke, K. (2006). Antidepressants and cognitive-behavioral therapy for symptom syndromes. CNS Spectrums, 11(3), 212–222.
97. Butler, A. C., Chapman, J. E., Forman, E. M., & Beck, A. T. (2006). The empirical status of cognitive-behavioral therapy: A review of meta-analyses [Abstract]. Clinical Psychology Review, 26(1), 17–31.
98. Morley, S., Eccleston, C., & Williams, A. (1999). Systematic review and meta-analysis of randomized controlled trials of cognitive behaviour therapy and behaviour therapy for chronic pain in adults, excluding headache. PAIN, 80(1–2), 1–13.
99. Morley, S., Williams, A., & Hussain, S. (2008). Estimating the clinical effectiveness of cognitive behavioural therapy in the clinic: Evaluation of a CBT informed pain management programme. PAIN, 137(3), 670–680.
100. S. Morley (personal communication, February 3, 2011).
101. Morley, S. (2011). Efficacy and effectiveness of cognitive behaviour therapy for chronic pain: Progress and some challenges. PAIN, 152(3), S99–S106.
102. Eccleston, C., Palermo, T. M., Williams, A. C., Lewandowski, A., & Morley, S. (2009). Psychological therapies for the management of chronic and recurrent pain in children and adolescents [Abstract]. Cochrane Database of Systematic Reviews, 2009(2), CD003968.
103. Macea, D. D., Gajos, K., Daglia Calil, Y. A., & Fregni, F. (2010). The efficacy of web-based cognitive behavioral interventions for chronic pain: A systematic review and meta-analysis [Abstract]. The Journal of Pain, 11(10), 917–929.
104. Jackson, J. L., O’ Malley, P. G., & Kroenke, K. (2006). Antidepressants and cognitive-behavioral therapy for symptom syndromes. CNS Spectrums, 11(3), 212–222.
105. Jensen, M. P., Turner, J. A., & Romano, J. M. (2001). Changes in beliefs, catastrophizing, and coping are associated with improvement in multidisciplinary pain treatment. Journal of Consulting and Clinical Psychology, 69(4), 655–662.
106. Edwards, R. R., Bingham, C. O., III, Bathon, J., & Haythornthwaite, J. A. (2006). Catastrophizing and pain in arthritis, fibromyalgia, and other rheumatic diseases. Arthritis Care & Research, 55(2), 325–332.
107. Cepeda, M. S., Carr, D. B., Lau, J., & Alvarez, H. (2006). Music for pain relief [Abstract]. Cochrane Database of Systematic Reviews, 2006(2), CD004843.
108. Ford, G. K., Moriarty, O., McGuire, B. E., & Finn, D. P. (2008). Investigating the effects of distracting stimuli on nociceptive behaviour and associated alterations in brain monoamines in rats. European Journal of Pain, 12(8), 970–979.
109. M. Jensen & D. Patterson (personal communication, February 2, 2010).
110. Hoffman, H. G. (2004). Virtual-reality therapy. Scientific American, 291, 58–64.
111. Hoffman, H. G., Patterson, D. R., Magula, J., Carrougher, G. J., Zeltzer, K., Dagadakis, S., et al. (2004). Water-friendly virtual reality pain control during wound care [Abstract]. Journal of Clinical Psychology, 60(2), 189–195.
112. Hoffman, H. G., Patterson, D. R., & Carrougher, G. J. (2000). Use of virtual reality for adjunctive treatment of adult burn pain during physical therapy: A controlled study [Abstract]. The Clinical Journal of Pain, 16(3), 244–250.
113. Patel, A., Schieble, T., Davidson, M., Tran, M. C. J., Schoenberg, C., Delphin, E., et al. (2006). Distraction with a handheld video game reduces pediatric preoperative anxiety [Abstract]. Pediatric Anesthesia, 16(10), 1019–1027.
114. Hoffman, H. G., Seibel, E. J., Richards, T. L., Furness, T. A., Patterson, D. R., & Sharar, S. R. (2006). Virtual reality helmet display quality influences the magnitude of virtual reality analgesia [Abstract]. The Journal of Pain, 7(11), 843–850.
115. Hoffman, H. G. (2004). Virtual-reality therapy. Scientific American, 291, 62.
116. Hoffman, H. G., Richards, T. L., Coda, B., Bills, A. R., Blough, D., Richards, A. L., et al. (2004). Modulation of thermal pain-related brain activity with virtual reality: Evidence from fMRI. Neuroreport, 15(8), 1245–1248.
117. Sprenger, C., Eippert, F., Finsterbusch, J., Bingel, U., Rose, M., & Buchel, C. (2012). Attention modulates spinal cord responses to pain. Current Biology, 22(11), 1019–1022.
118. Association for Applied Psychophysiology and Biofeedback. (n.d.). About biofeedback. Retrieved from http://www.aapb.org/i4a/pages/index.cfm?pageid=3463
119. Nestoriuc, Y., & Martin, A. (2007). Efficacy of biofeedback for migraine: A meta-analysis. PAIN, 128(1), 111–27.
120. Nestoriuc, Y., Martin, A., Rief, W., & Andrasik, F. (2008). Biofeedback treatment for headache disorders: A comprehensive efficacy review. Applied Psychophysiology and Biofeedback, 33(3), 125–140.
121. Frank, D. L., Khorshid, L., Kiffer, J. F., Moravec, C. S., & McKee, M. G. (2010). Biofeedback in medicine: Who, when, why and how? Mental Health in Family Medicine, 7(2), 85–91.
122. Jensen, M. P., Hakimian, S., Sherlin, L. H., & Fregni, F. (2009). New insights into neuromodulatory approaches for the treatment of pain. The Journal of Pain, 9(3), 193–199.
123. DeCharms, R. C., Maeda, F., Glover, G. H., Ludlow, D., Pauly, J. M., Soneji, D., et al. (2005). Control over brain activation and pain learned by using real-time functional MRI. Proceedings of the National Academy of Sciences, 102(51), 18626–18631.
124. S. Mackey (personal communication, April 14, 2012).
125. Foreman, J. (2003, April 22). A look at the science behind meditation. The Boston Globe, p. F15.
126. Kabat-Zinn, J. (1990). Full catastrophe living: Using the wisdom of your body and mind to face stress, pain, and illness. New York: Bantam Dell.
127. Goleman, D. (1988). The meditative mind: The varieties of meditative experience. New York: J. P. Tarcher.
128. Goldsmith, J. S. (1990). The art of meditation. New York: HarperCollins.
129. Gardner-Nix, J., & Costin-Hall, L. (2009). The mindfulness solution to pain: Step-by-step techniques for chronic pain management. Oakland, CA: New Harbinger.
130. Vowles, K. E., McCracken, L. M., & Dahl, J. C. (2010, May 7). Acceptance and commitment therapy and chronic pain. PowerPoint slides presented at the American Pain Society’s 29th Annual Meeting, Baltimore, MD.
131. Davidson, R. J., Kabat-Zinn, J., Schumacher, J., Rosenkranz, M., Muller, D., Santorelli, S. F., et al. (2003). Alterations in brain and immune function produced by mindfulness meditation. Psychosomatic Medicine, 65(4), 564–570.
132. Lazar, S. W., Kerr, C. E., Wasserman, R. H., Gray, J. R., Greve, D. N., Treadway, M. T., et al. (2005). Meditation experience is associated with increased cortical thickness. Neuroreport, 16(17), 1893–1897.
133. Grant, J. A., Courtemanche, J., Duerden, E. G., Duncan, G. H., & Rainville, P. (2010). Cortical thickness and pain sensitivity in zen meditators [Abstract]. Emotion, 10(1), 43–53.
134. Grant, J. A., Courtemanche, J., & Rainville, P. (2010). A non-elaborative mental stance and decoupling of executive and pain-related cortices predicts low pain sensitivity in Zen meditators [Abstract]. PAIN, 152(1), 150–156.
135. Lush, E., Salmon, P., Floyd, A., Studts, J. L., Weissbecker, I., & Sephton, S. E. (2009). Mindfulness meditation for symptom reduction in fibromyalgia: Psychophysiological correlates [Abstract]. Journal of Clinical Psychology in Medical Settings, 16(2), 200–207.
136. Grossman, P., Tiefenthaler-Gilmer, U., Raysz, A., & Kesper, U. (2007). Mindfulness training as an intervention for fibromyalgia: Evidence of postintervention and 3-year follow-up benefits in well-being [Abstract]. Psychotherapy and Psychosomatics, 76(4), 226–233.
137. Vago, D. R., & Nakamura, Y. (2011). Selective attentional bias towards pain-related threat in fibromyalgia: Preliminary evidence for effects of mindfulness meditation training. Cognitive Therapy and Research, 35(6), 581–594.
138. Schmidt, S., Grossman, P., Schwarzer, B., Jena, S., Naumann, J., & Walach, H. (2011). Treating fibromyalgia with mindfulness-based stress reduction: Results from a 3-armed randomized controlled trial [Abstract]. PAIN, 152(2), 361–369.
139. Zeidan, F., Martucci, K. T., Kraft, R. A., Gordon, N. S., McHaffie, J. G., & Coghill, R. C. (2011). Brain mechanisms supporting the modulation of pain by mindfulness meditation. The Journal of Neuroscience, 31(14), 5540–5548.
140. Zeidan, F., Gordon, N. S., Merchant, J., & Goolkasian, P. (2010). The effects of brief mindfulness meditation training on experimentally induced pain [Abstract]. The Journal of Pain, 11(3), 199–209.
141. Rosenzweig, S., Greeson, J. M., Reibel, D. K., Green, J. S., Jasser, S. A., & Beasley, D. (2010). Mindfulness-based stress reduction for chronic pain conditions: Variation in treatment outcomes and role of home meditation practice [Abstract]. Journal of Psychosomatic Research, 68(1), 29–36.
142. Brown, C. A., & Jones, A. K. P. (2010). Meditation experience predicts less negative appraisal of pain: Electrophysiological evidence for the involvement of anticipatory neural responses [Abstract]. PAIN, 150(3), 428–438.
143. Hölzel, B. K., Carmody, J., Vangel, M., Congleton, C., Yerramsetti, S. M., Gard, T., et al. (2011). Mindfulness practice leads to increases in regional brain gray matter density. Psychiatry Research: Neuroimaging, 191(1), 36–43.
144. Gard, T., Holzel, B. K., Sack, A. T., Hempel, H., Lazar, S. W., Vaitl, D., et al. (2012). Pain attenuation through mindfulness is associated with decreased cognitive control and increased sensory processing in the brain. Cerebral Cortex, 22(11), 2692–2702.
145. S. Lazar (personal communication, April 10, 2012).
146. Patterson, D. R., & Jensen, M. P. (2003). Hypnosis and clinical pain. Psychological Bulletin, 129(4), 495–521.
147. Barber, J. E. (1996). Hypnosis and suggestion in the treatment of pain: A clinical guide (p. 3). New York: W. W. Norton & Co.
148. Jensen, M. P., Ehde, D. M., Gertz, K. J., Stoelb, B. L., Dillworth, T. M., Hirsh, A. T., et al. (2011). Effects of self-hypnosis training and cognitive restructuring on daily pain intensity and catastrophizing in individuals with multiple sclerosis and chronic pain. International Journal of Clinical and Experimental Hypnosis, 59(1), 45–63.
149. Jensen, M. P., Barber, J., Romano, J. M., Hanley, M. A., Raichle, K. A., Molton, I. R., et al. (2009). Effects of self-hypnosis training and EMG biofeedback relaxation training on chronic pain in persons with spinal-cord injury. International Journal of Clinical and Experimental Hypnosis, 57(3), 239–268.
150. Zeltzer, L., & LeBaron, S. (1982). Hypnosis and nonhypnotic techniques for reduction of pain and anxiety during painful procedures in children and adolescents with cancer. The Journal of Pediatrics, 101(6), 1032–1035.
151. Patterson, D. R., & Jensen, M. P. (2003). Hypnosis and clinical pain. Psychological Bulletin, 129(4), 495–521.
152. M. Jensen & D. Patterson (personal communication, February 2, 2010).
153. Jensen, M., McArthur, K., Barber, J., Hanley, M., Engel, J., Romano, J., et al. (2006). Satisfaction with, and the beneficial side effects of, hypnotic analgesia. International Journal of Clinical and Experimental Hypnosis, 54(4), 432–447.
154. Prkachin, K. M., Solomon, P. E., & Ross, J. (2007). Underestimation of pain by health-care providers: Towards a model of the process of inferring pain in others [Abstract]. Canadian Journal of Nursing Research, 39(2), 88–106.
155. K. Prkachin (personal communication, October 20, 2010).
156. Austin, J. H. (2009). Selfless insight: Zen and the meditative transformations of consciousness (p. 213). Cambridge, MA: MIT Press.
157. Jamison, R. N. (2011). Nonspecific treatment effects in pain medicine. PAIN: Clinical Updates, 19(2), 1–7.
158. Jackson, P. L., Meltzoff, A. N., & Decety, J. (2005). How do we perceive the pain of others? A window into the neural processes involved in empathy. NeuroImage, 24(3), 771–779.
159. M. Loggia (personal communication, February 1, 2011).
160. Iacoboni, M., & Dapretto, M. (2006). The mirror neuron system and the consequences of its dysfunction [Abstract]. Nature Reviews Neuroscience, 7(12), 942–951.
161. Dapretto, M., Davies, M. S., Pfeifer, J. H., Scott, A. A., Sigman, M., Bookheimer, S. Y., et al. (2005). Understanding emotions in others: Mirror neuron dysfunction in children with autism spectrum disorders [Abstract]. Nature Neuroscience, 9(1), 28–30.
162. Iacoboni, M. (2009). Imitation, empathy, and mirror neurons. Annual Review of Psychology, 60, 653–670.
163. Avenanti, A., Paluello, I. M., Bufalari, I., & Aglioti, S. M. (2006). Stimulus-driven modulation of motor-evoked potentials during observation of others’ pain [Abstract]. NeuroImage, 32(1), 316–324.
164. Avenanti, A., Bueti, D., Galati, G., & Aglioti, S. M. (2005). Transcranial magnetic stimulation highlights the sensorimotor side of empathy for pain [Abstract]. Nature Neuroscience, 8(7), 955–960.
165. Fecteau, S., Pascual-Leone, A., & Theoret, H. (2008). Psychopathy and the mirror neuron system: Preliminary findings from a non-psychiatric sample. Psychiatry Research, 160, 137–144.
166. Deyo, K. S., Prkachin, K. M., & Mercer, S. R. (2004). Development of sensitivity to facial expression of pain. PAIN, 107(1–2), 16–21.
167. Coan, J. A., Schaefer, H. S., & Davidson, R. J. (2006). Lending a hand: Social regulation of the neural response to threat. Psychological Science, 17(12), 1032–1039.
168. Loggia, M. L., Mogil, J. S., & Bushnell, M. C. (2008). Empathy hurts: Compassion for another increases both sensory and affective components of pain perception. PAIN, 136(1–2), 168–176.
169. Langford, D. J., Crager, S. E., Shehzad, Z., Smith, S. B., Sotocinal, S. G., Levenstadt, J. S., et al. (2006). Social modulation of pain as evidence for empathy in mice [Abstract]. Science, 312(5782), 1967–1970.
170. Thomson, H. (2010, March). We feel your pain: Extreme empaths. The New Scientist, (2751), 43–45.
171. Jackson, T., Iezzi, T., Chen, H., Ebnet, S., & Eglitis, K. (2005). Gender, interpersonal transactions, and the perception of pain: An experimental analysis [Abstract]. The Journal of Pain, 6(4), 228–236.
172. Keefe, F. J., & Somers, T. J. (2010). Psychological approaches to understanding and treating arthritis pain. Nature Reviews Rheumatology, 6(4), 210–216.
173. Singer, T., Seymour, B., O’Doherty, J., Kaube, H., Dolan, R. J., & Frith, C. D. (2004). Empathy for pain involves the affective but not sensory components of pain. Science, 303(5661), 1157–1162.
174. Botvinick, M., Jha, A. P., Bylsma, L. M., Fabian, S. A., Solomon, P. E., & Prkachin, K. M. (2005). Viewing facial expressions of pain engages cortical areas involved in the direct experience of pain. NeuroImage, 25(1), 312–319.
175. Singer, T., Seymour, B., O’Doherty, J. P., Stephan, K. E., Dolan, R. J., & Frith, C. D. (2006). Empathic neural responses are modulated by the perceived fairness of others. Nature, 439(7075), 466–469.
1. H. Neizer (personal communication, October 2009).
2. Fishbain, D. A., Cole, B., Lewis, J., Rosomoff, H. L., & Rosomoff, R. S. (2008). What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Medicine, 9(4), 444–459.
3. L. Webster (personal communication, February 26, 2011).
4. Szalavitz, M. (2011, November 2). Are doctors really to blame for the overdose epidemic? [Blog post]. Retrieved from http://healthland.time.com/2011/11/02/are-doctors-really-to-blame-for-the-overdose-epidemic
5. Institute of Medicine, Committee on Advancing Pain Research, Care, and Education. (2011). Relieving pain in America: A blueprint for transforming prevention, care, education and research (p. S-3). Prepublication copy. Washington, DC: National Academies Press.
6. Institute of Medicine, Committee on Advancing Pain Research, Care, and Education. (2011). Relieving pain in America: A blueprint for transforming prevention, care, education and research (pp. 3–28). Prepublication copy. Washington, DC: National Academies Press.
7. A. Paolitto (personal communication, October 8, 2012).
8. A. Kolodny (personal communication, October 5, 2012).
9. A. Kolodny (personal communication, March 26, 2013).
10. Orlando Business Journal. (2004, February 27). Orlando Sentinel reporter resigns, two editors reassigned in OxyContin story fallout. Retrieved from http://www.bizjournals.com/orlando/stories/2004/02/23/daily37.html
11. Libby, R. T. (2005, June 16). Treating doctors as drug dealers: The DEA’s war on prescription painkillers. Policy Analysis, (545), 1–27. Retrieved from http://www.cato.org/pubs/pas/pa545.pdf
12. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. (2011, November). Prescription painkiller overdoses in the US. Retrieved from http://www.cdc.gov/VitalSigns/pdf/2011-11-vitalsigns.pdf.
13. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. (2011, November). Policy impact: Prescription painkiller overdoses. Retrieved from http://www.cdc.gov/homeandrecreationalsafety/rxbrief
14. Paulozzi, L., Jones, C. M., Mack, K. A., & Rudd, R. A. (2011). Vital signs: Overdoses of prescription opioid pain relievers—United States, 1999–2008. Morbidity and Mortality Weekly Report, 60(43), 1487–1492.
15. Warner, M., Chen, L. H., Makuc, D. M., Anderson, R. N., & Minino, A. M. (2011, December). Drug poisoning deaths in the United States, 1980–2008 [NCHS Data Brief, No. 81]. Retrieved from http://www.cdc.gov/nchs/data/databriefs/db81.pdf
16. M. Von Korff (personal communication, October 5, 2012).
17. Centers for Disease Control and Prevention. (n.d.). Prescription painkiller overdoses in the U.S. Retrieved from http://www.cdc.gov/Features/VitalSigns/PainkillerOverdoses
18. Patrick, S. W., Schumacher, R. E., Benneyworth, B. D., Krans, E. E., McAllister, J. M., & Davis, M. M. (2012). Neonatal abstinence syndrome and associated health care expenditures—United States 2000–2009. Journal of the American Medical Association, 307(18), 1934–1040.
19. CNNMoney.com. (2007, July 20). Purdue in $634 million settlement over OxyContin [Press release]. Retrieved from http://money.cnn.com/2007/07/20/news/companies/purdue/index.htm
20. National Institute on Drug Abuse. (2011, April 5). Analysis of opioid prescription practices finds area of concern [Press release]. Retrieved from http://www.drugabuse.gov/news-events/news-releases/2011/04/analysis-opioid-prescription-practices-finds-areas-concern
21. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. (2011, November). Policy impact: Prescription painkiller overdoses [Issue brief]. Retrieved from http://www.cdc.gov/homeandrecreationalsafety/rxbrief
22. Paulozzi, L., Jones, C. M., Mack, K. A., & Rudd, R. A. (2011). Vital signs: Overdoses of prescription opioid pain relievers—United States, 1999–2008. Morbidity and Mortality Weekly Report, 60(43), 1487–1492.
23. Centers for Disease Control and Prevention WONDER. (2013, February). Pharmaceutical overdose deaths, US, 2010. Retrieved from http://wonder.cdc.gov
24. C. Lenard (personal communication, March 27, 2013).
25. Adhikari, B., Kahende, J., Malarcher, A., Pechacek, T., & Tong, V. (2008). Smoking-attributable mortality, years of potential life lost, and productivity losses—United States, 2000–2004. Morbidity and Mortality Weekly Report, 57(45), 1226–1228.
26. Centers for Disease Control and Prevention. (2008). Alcohol and public health: Alcohol-Related Disease Impact (ARDI)—Average for United States 2001–2005—Alcohol-attributable deaths due to excessive alcohol use. Retrieved from http://apps.nccd.cdc.gov/DACH_ARDI/default/default.aspx
27. Lanza, F. L., Chan, F. K. L., & Quigley, E. M. M. (2009). Guidelines for prevention of NSAID-related ulcer complications. American Journal of Gastroenterology, 104, 728–738.
28. Wiegand, T. J., Wax, P. M., Schwartz, T., Finkelstein, Y., Gorodetsky, R., Brent, J., et al. (2012). The Toxicology Investigators Consortium case registry—the 2011 experience. Journal of Medical Toxicology, 8(4), 360–377.
29. Cave, D., & Schmidt, M. S. (2012, July 17). Rise in pill abuse forces new look at U.S. drug fight. The New York Times, p. A1.
30. Global Commission on Drug Policy. (2011, June). War on Drugs: Report of the Global Commission on Drug Policy. Retrieved from http://www.globalcommissionondrugs.org/wp-content/themes/gcdp_v1/pdf/Global_Commission_Report_English.pdf
31. Katz, J. M. (2011, June 2). Commission declares drug war failure, urges legalization. The Boston Globe, p. A6.
32. Brown, D. (2001, April 2). Nuclear power is safest way to make electricity, according to study. The Washington Post. Retrieved from http://www.washingtonpost.com/national/nuclear-power-is-safest-way-to-make-electricity-according-to-2007-study/2011/03/22/AFQUbyQC_story.html
33. Ropeik, D. (2011). How risky is it, really? Why our fears don’t always match the facts (pp. 26–261). New York: McGraw-Hill.
34. Brooks, D. (2011). The social animal: The hidden sources of love, character, and achievement (p. x). New York: Random House.
35. Catan, T., Barrett, D., & Martin, T. W. (2012, October 5). Prescription for addiction [Saturday essay]. The Wall Street Journal. Retrieved from http://online.wsj.com/article/SB10000872396390444223104578036933277566700.html
36. Ballantyne, J. C. (2009). U.S. opioid risk management initiatives. PAIN: Clinical Updates, 17(6), 1–5.
37. R. Twillman (personal communication, June 1, 2011).
38. Paul, R. (2004, April 19). The federal war on pain relief [Blog post]. Retrieved from http://www.ronpaularchive.com/2004/04/the-federal-war-on-pain-relief/
39. Musto, D. F. (1999). The American disease: Origins of narcotic control (3rd ed.). Oxford, UK: Oxford University Press.
40. Ballantyne, J. C. & Shin, N. S. (2008). Efficacy of opioids for chronic pain: A review of the evidence. The Clinical Journal of Pain, 24(6), 469–478.
41. Ballantyne, J. C. (2009). U.S. opioid risk management initiatives. PAIN: Clinical Updates, 17(6), 1–5.
42. Zogenix. (2012, May 2). NDA submitted for Zohydro [Press release]. Retrieved from http://www.drugs.com/nda/zohydro_120502.html
43. CBC News Canada. (2011, December 26). More powerful painkiller coming: Hydrocodone raises fears of abuse. Retrieved from http://www.cbc.ca/news/health/story/2011/12/26/hydrocodone-painkiller-abuse.html
44. Eban, K. (2011). Painful medicine: What the strange saga of Purdue Pharma—and its $3 billion drug, OxyContin—tells us about our national dependence on painkillers. Fortune, 164(8), 144.
45. CBC News Canada. (2012, March 8). OxyContin marketing blamed for addiction epidemic. Retrieved from http://www.cbc.ca/news/canada/story/2012/03/08/oxycontin-marketing.html
46. Meier, B. (2007, May 10). In guilty plea, OxyContin maker to pay $600 million. The New York Times. Retrieved from http://www.nytimes.com/2007/05/10/business/11drug-web.html?pagewanted=all
47. Purdue Pharma. (2007, May 10). Statement of Purdue Pharma regarding resolution of the federal investigation in the western district of Virginia [Press release]. Retrieved from http://www.evaluatepharma.com/Universal/View.aspx?type=Story&id=126370
48. CNNMoney.com. (2007, July 20). Purdue in $634 million settlement over OxyContin [Press release]. Retrieved from http://money.cnn.com/2007/07/20/news/companies/purdue/index.htm
49. IMS HEALTH. (n.d.). Top U.S. pharmaceutical products by spending. Retrieved from http://www.imshealth.com/ims/Global/Content/Corporate/Press%20Room/Top-Line%20Market%20Data%20&%20Trends/2011%20Top-line%20Market%20Data/Top_Products_by_Sales.pdf
50. Ornstein, C., & Weber, T. (2012, May 8). American Pain Foundation shuts down as senators launch investigation of prescription narcotics. Retrieved from http://www.propublica.org/article/senate-panel-investigates-drug-company-ties-to-pain-groups
51. American Pain Foundation. (2010). 2010 Annual Report (p. 16). Retrieved from http://s3.documentcloud.org/documents/277604/apf-2010-annual-report.pdf.
52. Ballantyne, J. (2011). Pain medicine: Repairing a fractured dream. Anesthesiology, 114(2), 243–246.
53. IMS Health. (n.d.). Top therapeutic classes by U.S. dispensed prescription. Retrieved from http://www.imshealth.com/deployedfiles/ims/Global/Content/Corporate/Press%20Room/Top-Line%20Market%20Data%20&%20Trends/2011%20Top-line%20Market%20Data/Top_Therapy_Classes_by_RX.pdf
54. Ballantyne, J. C. (2009). U.S. opioid risk management initiatives [Table 1: Summary of U.S. retail drug purchases, 1997–2005]. PAIN: Clinical Updates, 17(6), 2.
55. IMS Health. (n.d.). Top therapeutic classes by U.S. dispensed prescription. Retrieved from http://www.imshealth.com/deployedfiles/ims/Global/Content/Corporate/Press%20Room/Top-Line%20Market%20Data%20&%20Trends/2011%20Top-line%20Market%20Data/Top_Therapy_Classes_by_RX.pdf
56. B. Linton (personal communication, March 27, 2013).
57. K. Bush (personal communication, April 25, 2011).
58. R. Twillman (personal communication, June 1, 2011).
59. Department of Defense. (2010, January 5). Department of Defense announces results of 2008 health related behaviors survey [Press release]. Retrieved from http://www.rti.org/newsroom/news.cfm?objectid=9E651A68-5056-B172-B873C3640C367541
60. Office of National Drug Control Policy. (2011, April 19). Obama administration releases action plan to address national prescription drug abuse epidemic; Announces FDA action requiring drug makers to develop education program for prescribers about safe use of opioids [Press release]. Retrieved from http://www.justice.gov/dea/pubs/pressrel/pr041911.html
61. D. E. Hoffmann (personal communication, October 5, 2010).
62. Hoffmann, D. (2008). Treating pain v. reducing drug diversion and abuse: Recalibrating the balance in our drug control laws and policies. St. Louis University Journal of Health Law and Policy, 1(2), 256.
63. Executive Office of the President of the United States. (2011). Epidemic: Responding to America’s prescription drug abuse crisis (p. 5). Retrieved from http://www.whitehouse.gov/sites/default/files/ondcp/issues-content/prescription-drugs/rx_abuse_plan_0.pdf
64. Valencia, M. J. (2011, March 4). Doctor indicted in 6 drug fatalities. The Boston Globe, pp. A1, A9.
65. Van Zeller, M. (2009, October 15). The OxyContin express [Webisode]. Vanguard. Retrieved from http://current.com/groups/vanguard-theoxycontin-express
66. Anderson, C. (2011, April 20). Deadly abuse puts focus on “pill mills.” The Boston Globe. Retrieved from http://articles.boston.com/2011-04-20/news/29451932_1_cocaine-deaths-oxycodone-pills-prescription-drugs
67. LaMendola, B., & Campbell, A. (2011, February 23). Feds, police raid 11 south Florida pill mills. The South Florida Sun-Sentinel. Retrieved from http://articles.sun-sentinel.com/2011-02-23/health/fl-pill-mill-raids-20110223_1_pain-clinics-pill-mills-pain-pill
68. United States Drug Enforcement Administration. (2011, October 28). DEA administrator, attorney general announce enforcement efforts against illegal prescription drug distributors in Florida [Press release]. Retrieved from http://www.justice.gov/dea/pubs/pressrel/pr102811.html
69. Hoffmann, D. (2008). Treating pain v. reducing drug diversion and abuse: Recalibrating the balance in our drug control laws and policies. St. Louis University Journal of Health Law and Policy, 1(2), 256.
70. B. L. Carreno (personal communication, April 11, 2011).
71. Richard, J., & Reidenberg, M. M. (2005). The risk of disciplinary action by state medical boards against physicians prescribing opioids. Journal of Medical Licensure and Discipline, 91(2), 14–19.
72. Goldenbaum, D. M., Christopher, M., Gallagher, R. M., Fishman, S., Payne, R., Joranson, D., et al. (2008). Physicians charged with opioid analgesic-prescribing offenses. Pain Medicine, 9(6), 737–747.
73. Center for Practical Bioethics, National Association of Attorneys General, & Federation of State Medical Boards. (2008, September 9). Few physicians actually tried or sanctioned for improperly prescribing pain medications [Press release]. Retrieved from http://drugcontrol.flgov.com/pdmp/documents/Few_physicians_tried_or_sanctioned.pdf
74. Hoffmann, D. (2008). Treating pain v. reducing drug diversion and abuse: Recalibrating the balance in our drug control laws and policies. St. Louis University Journal of Health Law and Policy, 1(2), 231–309.
75. R. Sauber (personal communication, February 23, 2011).
76. L. Webster (personal communication, February 17, 2011).
77. L. Webster (personal communication, May 25, 2011).
78. J. Dahl (personal communication, March 19, 2013).
79. Bates, C., Laciak, R., Southwick, A., & Bishoff, J. (2011). Overprescription of postoperative narcotics: A look at postoperative pain medication delivery, consumption and disposal in urological practice. The Journal of Urology, 185(2), 551–555.
80. Kehlet, H. (2005). Postoperative opioid sparing to hasten recovery: What are the issues? Anesthesiology, 102(6), 1083–1085.
81. Kehlet, H., Rung, G. W., & Callesen, T. (1996). Postoperative opioid analgesia: Time for a reconsideration? Journal of Clinical Anesthesia, 8(6), 441–445.
82. Von Korff, M. R. (2010, May). Trends and risks of chronic opioid therapy among the elderly. Paper presented at the 5th Annual NIH Pain Consortium Symposium, Washington, DC.
83. M. Von Korff (personal communication, February 23, 2011).
84. C. Stencel (personal communication, March 27, 2012).
85. Portenoy, R. K., Ugarte, C., Fuller, I., & Haas, G. (2004). Population-based survey of pain in the United States: Differences among White, African-American, and Hispanic subjects. The Journal of Pain, 5(6), 317–328.
86. The Mayday Fund. (2009). A call to revolutionize chronic pain care in America: An opportunity in health care reform. Retrieved from http://www.maydaypainreport.org/docs/A%20Call%20to%20Revolutionize%20Chronic%20Pain%20Care%20in%20America%2003.04.10.pdf
87. Shi Q., Langer, G., Cohen, J., & Cleeland, C. S. (2007). People in pain: How do they seek relief? The Journal of Pain, 8(8), 624–636.
88. Nwokeji, E., Rascati, K., Brown, C., & Eisenberg, A. (2007). Influences of attitudes on family physicians’ willingness to prescribe long-acting opioid analgesics for patients with chronic nonmalignant pain. Clinical Therapeutics, 29(11), 2589–2602.
89. Quill, T. E., & Meier, D. (2006). The big chill—inserting the DEA into end-of-life care [Perspective]. New England Journal of Medicine, 354, 1–3.
90. Cherny, N. I., Baselga, J., de Conno, F., & Radbruch, L. (2010). Formulary availability and regulatory barriers to accessibility of opioids for cancer pain in Europe: A report from the ESMO/EAPC opioid policy initiative. Annals of Oncology, 21(3), 615–626.
91. Human Rights Watch. (2009, March). “Please do not make us suffer anymore …”: Access to pain treatment as a human right. Retrieved from www.hrw.org/en/node/81079/section/3
92. Human Rights Watch. (2009, October). Unbearable pain: India’s obligation to ensure palliative care. Retrieved from http://www.hrw.org/sites/default/files/reports/health1009web.pdf
93. World Health Organization. (2009, February). World Health Organization Briefing Note—February 2009: Access to controlled medications programme. Retrieved from http://www.who.int/medicines/areas/quality_safety/ACMP_BrNoteGenrl_EN_Feb09.pdf
94. Cleary, J. F., Hutson, P., & Joranson, D. (2010). Access to therapeutic opioid medications in Europe by 2011? Fifty years on from the Single Convention on Narcotic Drugs [Editorial]. Palliative Medicine, 24(2), 109–110.
95. Human Rights Watch. (2009, March). “Please do not make us suffer anymore …”: Access to pain treatment as a human right. Retrieved from www.hrw.org/en/node/81079/section/3
96. Chapman, C. R., Lipschitz, D. L., Angst, M. S., Chou, R., Densico, R. C., Donaldson, G. W., et al. (2010). Opioid pharmacotherapy for chronic non-cancer pain in the United States: A research guideline for developing an evidence-base [Opioid pharmacotherapy research guideline]. The Journal of Pain, 11(9), 810.
97. Ross, E. L., Holcomb, C., & Jamison, R. N. (2009). Addressing abuse and misuse of opioid analgesics. Drug Benefit Trends, 21(2), 54–63.
98. Institute of Medicine, Committee on Advancing Pain Research, Care, and Education. (2011). Relieving pain in America: A blueprint for transforming prevention, care, education and research (p. GL–1). Prepublication copy. Washington, DC: National Academies Press.
99. American Society of Addiction Medicine. (2011, April 12). Public policy statement: Definition of addiction. Retrieved from http://www.asam.org/for-the-public/definition-of-addiction
100. American Society of Addiction Medicine. (2011, August 15). ASAM releases new definition of addiction [Press release]. Retrieved from http://www.eurekalert.org/pub_releases/2011-08/asoa-arn072111.php
101. Szalavitz, M. (2011, August 16). Why the new definition of addiction, as “brain disease,” falls short. Time. Retrieved from http://healthland.time.com/2011/08/16/why-the-new-definition-of-addiction-as-brain-disease-falls-short
102. J. Dahl (personal communication, March 17, 2013).
103. Ballantyne, J. C., Sullivan, M. D., & Kolodny, A. (2012). Opioid dependence vs addiction: A distinction without a difference? Archives of Internal Medicine, 172(17),1342–1343.
104. A. Kolodny (personal communication, October 5, 2012).
105. M. Maglio (personal communication, March 23, 2010)
106. R. Portenoy (personal communication, March 9, 2011).
107. R. Portenoy (personal communication, September 10, 2009).
108. H. Heit (personal communication, March 1, 2011).
109. L. Webster (personal communication, May 17, 2012).
110. Gelernter, J., Panhuysen, C., Wilcox, M., Hesselbrock, V., Rounsaville, B., Poling, J., et al. (2006). Genomewide linkage scan for opioid dependence and related traits. American Journal of Human Genetics, 78(5), 759–769.
111. L. Webster (personal communication, March 4, 2011).
112. S. Simson (personal communication, May 24, 2012).
113. Minozzi, S., Amato, L., & Davoli, M. (2013). Development of dependence following treatment with opioid analgesics for pain relief: A systematic review. Addiction 108(4), 688–698.
114. Fishbain, D. A., Rosomoff, H. L., & Rosomoff, R. S. (1992). Drug abuse, dependence, and addiction in chronic pain patients. The Clinical Journal of Pain, 8(2), 77–85.
115. Fishbain, D. A., Cole, B., Lewis, J., Rosomoff, H. L., & Rosomoff, R. S. (2008). What percentage of chronic nonmalignant pain patients exposed to chronic opioid analgesic therapy develop abuse/addiction and/or aberrant drug-related behaviors? A structured evidence-based review. Pain Medicine, 9(4), 444–459.
116. Webster, L. R., & Webster, R. M. (2005). Predicting aberrant behaviors in opioid-treated patients: Preliminary validation of the opioid risk tool. Pain Medicine, 6(6), 432–442.
117. Fleming, M. F., Balousek, S. L., Klessig, C. L., Mundt, M. P., & Brown, D. D. (2007). Substance use disorders in a primary care sample receiving daily opioid therapy. The Journal of Pain, 8(7), 573–582.
118. Chapman, C. R., Lipschitz, D. L., Angst, M. S., Chou, R., Densico, R. C., Donaldson, G. W., et al. (2010). Opioid pharmacotherapy for chronic non-cancer pain in the United States: A research guideline for developing an evidence-base [Opioid pharmacotherapy research guideline]. The Journal of Pain, 11(9), 810.
119. Noble, M., Treadwell, J. R., Tregear, S. J., Coates, V. H., Wiffen, P. J., Akafomo, C., et al. (2010). Long-term opioid management for chronic noncancer pain [Intervention review]. Cochrane Database of Systematic Reviews, 2010(1), CD006605.
120. Banta-Green, C. J., Merrill, J. O., Doyle, S. R., Boudreau, D. M., & Calsyn, D. A. (2009). Opioid use behaviors, mental health and pain—development of a typology of chronic pain patients. Drug and Alcohol Dependence, 104(1–2), 34–42.
121. M. Von Korff (personal communication, February 28, 2011).
122. Kauffman, J. F. (2011). Strategies for managing pain & opioid dependence [PowerPoint slides]. Copy in possession of author.
123. J. Kauffman (personal communication, February 23, 2011).
124. Von Korff, M. (2010). Commentary on Boscarino et al. (2010): Understanding the spectrum of opioid abuse, misuse and harms among chronic opioid therapy patients. Addiction, 105(10), 1783–1784.
125. Wasan, A., Butler, S. F., Budman, S. H., Benoit, C., Fernandez, K., & Jamison, R. N. (2007). Psychiatric history and psychologic adjustment as risk factors for aberrant drug-related behavior among patients with chronic pain. The Clinical Journal of Pain, 23(4), 307–315.
126. Jamison, R. N., Ross, E. L., Michna, E., Chen, L. Q., Holcomb, C., & Wasan A. D. (2010). Substance misuse treatment for high-risk chronic pain patients on opioid therapy: A randomized trial. PAIN, 150(3), 390–400.
127. Jamison, R. N., Link, C. L., & Marceau, L. D. (2009). Do pain patients at high risk for substance misuse experience more pain? A longitudinal outcomes study. Pain Medicine, 10(6), 1084–1094.
128. Von Korff, M. (2010). Commentary on Boscarino et al. (2010): Understanding the spectrum of opioid abuse, misuse and harms among chronic opioid therapy patients. Addiction, 105(10), 1783–1784.
129. World Health Organization. (2009, February). World Health Organization Briefing Note—February 2009: Access to controlled medications programme. Retrieved from http://www.who.int/medicines/areas/quality_safety/ACMP_BrNoteGenrl_EN_Feb09.pdf
130. Foreman, J. (2008, September 15). When pain arrives and help does not. The Boston Globe. Retrieved from http://judyforeman.com/columns/when-pain-arrives-and-help-does-not
131. National Institute on Drug Abuse. (2011, April 5). Analysis of opioid prescription practices finds areas of concern [Press release]. Retrieved from http://www.drugabuse.gov/news-events/news-releases/2011/04/analysis-opioid-prescription-practices-finds-areas-concern
132. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. (2011, November). Policy impact: Prescription painkiller overdoses. Retrieved from http://www.cdc.gov/homeandrecreationalsafety/rxbrief
133. U.S. Department of Justice, National Drug Intelligence Center. (2010, February). National drug threat assessment 2010 [Executive summary]. Retrieved from http://www.justice.gov/ndic/pubs38/38661/execSum.htm
134. Chapman, C. R., Lipschitz, D. L., Angst, M. S., Chou, R., Densico, R. C., Donaldson, G. W., et al. (2010). Opioid pharmacotherapy for chronic non-cancer pain in the United States: A research guideline for developing an evidence-base [Opioid pharmacotherapy research guideline]. The Journal of Pain, 11(9), 810.
135. Dunn, K. M., Saunders, K. W., Rutter, C. M., Banta-Green, C. J., Merrill, J. O., Sullivan, M. D., et al. (2010). Opioid prescriptions for chronic pain and overdose. Annals of Internal Medicine, 152, 85–92.
136. Bohnert, A. S. B., Valenstein, M., Bair, M. J., Ganoczy, D., McCarthy, J. F., Ilgen, M. A., et al. (2011). Association between opioid prescribing patterns and opioid overdose-related deaths. Journal of the American Medical Association, 305(13), 1315–1321.
137. Gomes, T., Mamdani, M. M., Dhalla, I. A., Paterson, J. M., & Juurlink, D. N. (2011). Opioid dose and drug-related mortality in patients with nonmalignant pain. Archives of Internal Medicine, 171(7), 686–691.
138. Hall, A. J., Logan, J. E., Toblin, R. L., Kaplan, J. A., Kraner, J. C., Bixler, D., et al. (2008). Patterns of abuse among unintentional pharmaceutical overdose fatalities. Journal of the American Medical Association, 300(22), 2613–2620.
139. Arria, A. M., Garnier-Dykstra, L. M., Caldeira, K. M., Vincent, K. B., & O’ Grady, K. E. (2001). Prescription analgesic use among young adults: Adherence to physician instructions and diversion. Pain Medicine, 12(6), 898–903.
140. Cruciani, R., Fine, P., & January, C. (2010, May 8). Methadone prescribing: Everything you wanted to know but were afraid to ask. Paper presented at the 29th Annual Scientific Meeting of the American Pain Society Meeting, Baltimore, MD.
141. J. Dahl (personal communication, May 24, 2011).
142. H. Heit (personal communication, May 18, 2012).
143. D. Carr (personal communication, April 23, 2012).
144. L. Webster (personal communication, May 17, 2012).
145. U.S. Food and Drug Administration. (2006, November 27). Public health advisory: Methadone use for pain control may result in death and life-threatening changes in breathing and heart beat [Press release]. Retrieved from http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/PublicH
146. J. Kauffman (personal communication, February 23, 2011).
147. Seattle Times staff. (2012, April 16). Seattle Times methadone investigation wins Pulitzer Prize. The Seattle Times. Retrieved from http://seattletimes.nwsource.com/html/localnews/2017994882_pulitzer17m.html
148. Chapman, C. R., Lipschitz, D. L., Angst, M. S., Chou, R., Densico, R. C., Donaldson, G. W., et al. (2010). Opioid pharmacotherapy for chronic non-cancer pain in the United States: A research guideline for developing an evidence-base [Opioid pharmacotherapy research guideline]. The Journal of Pain, 11(9), 807–829.
149. J. Dahl (personal communication, March 17, 2013).
150. Saunders, K. W., Dunn, K. M., Merrill, J. O., Sullivan, M., Weisner, C., Braden, J. B., et al. (2010). Relationship of opioid use and dosage levels to fractures in older chronic pain patients. Journal of General Internal Medicine, 25(4), 310–315.
151. National Osteoporosis Foundation. (2011). Fast facts. Retrieved from http://www.nof.org/node/40
152. Rajagopal, A., Vassilopoulou-Sellin, R., Palmer, J. L., Kaur, G., & Bruera, E. (2003). Hypogonadism and sexual dysfunction in male cancer survivors receiving chronic opioid therapy. Journal of Pain Symptom Management, 26(5), 1055–1061.
153. Rubinstein, A., Carpenter, D. M., & Minkoff, J. (2013). Hypogonadism in men with chronic pain linked to the use of long-acting rather than short-acting opioids. The Clinical Journal of Pain. Advance online publication. Retrieved from http://journals.lww.com/clinicalpain/Abstract/publishahead/Hypogonadism_in_Men_With_Chronic_Pain_Linked_to.99660.aspx
154. J. Dahl (personal communication, March 17, 2013).
155. Katz, M. H. (2010). Long-term opioid treatment of nonmalignant pain: A believer loses his faith [Editorial]. Archives of General Medicine, 170(16), 1422–1423.
156. Von Korff, M. (2010). Commentary on Boscarino et al. (2010): Under-standing the spectrum of opioid abuse, misuse and harms among chronic opioid therapy patients. Addiction, 105(10), 1783–1784.
157. Chapman, C. R., Lipschitz, D. L., Angst, M. S., Chou, R., Densico, R. C., Donaldson, G. W., et al. (2010). Opioid pharmacotherapy for chronic non-cancer pain in the United States: A research guideline for developing an evidence-base [Opioid pharmacotherapy research guideline]. The Journal of Pain, 11(9), 807–829.
158. Chu, L. F., Angst, M. S., & Clark, D. (2008). Opioid-induced hyperalgesia in humans: Molecular mechanisms and clinical considerations [Special topic series]. The Clinical Journal of Pain, 24(6), 479–496.
159. L. Watkins (personal communication, October 28, 2009).
160. Chu, L. F., Angst, M. S., & Clark, D. (2008). Opioid-induced hyperalgesia in humans: Molecular mechanisms and clinical considerations [Special topic series]. The Clinical Journal of Pain, 24(6), 479–496.
161. US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration. (2010, September). Results from the 2009 National Survey on Drug Use and Health: Volume I. Summary of national findings (HHS Publication No. SMA 10-4586 Findings). Retrieved from http://oas.samhsa.gov/NSDUH/2k9NSDUH/2k9ResultsP.pdf
162. United States Drug Enforcement Administration. (2012, September 25). DEA holds its fifth prescription drug take-back day September 29 as public participation continues to rise [Press release]. Retrieved from http://www.justice.gov/dea/divisions/hq/2012/hq092512.shtml
163. Smarxt Disposal. (n.d.). Smarxt disposal: A prescription for a healthy planet. Retrieved from www.smarxtdisposal.net/index.html
164. Inciardi, J. A., Surratt, H. L., Kurtz, S. P., & Cicero, T. J. (2007). Mechanisms of prescription drug diversion among drug-involved club- and street-based populations. Pain Medicine, 8(2), 171–183.
165. Institute of Medicine, Committee on Advancing Pain Research, Care, and Education. (2011). Relieving pain in America: A blueprint for transforming prevention, care, education and research (pp. 2–26). Prepublication copy. Washington, DC: National Academies Press.
166. Fisch, M. J., Lee, J-W., Weiss, M., Wagner, L. I., Chang, V. T., Cella, D., et al. (2012). Prospective, observational study of pain and analgesic prescribing in medical oncology outpatients with breast, colorectal, lung, or prostate cancer. Journal of Clinical Oncology, 30(16), 1980–1988.
167. Ackerman, T. (2012, April 19). Pain treatment lacking for a third of cancer patients, study says. Houston Chronicle. Retrieved from http://www.chron.com/news/houston-texas/article/A-third-of-cancer-patients-pain-3496068.php
168. T. Fersch (personal communication, March 9, 2011).
169. R. Jamison (personal communication, February 14, 2011).
170. Chou, R., Fanciullo, G. J., Fine, P. G., Adler, J. A., Ballantyne, J. C., Davies, P., et al. (2009). Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. The Journal of Pain, 10(2), 113–130.
171. Ballantyne, J. C., & Shin, N. S. (2008). Efficacy of opioids for chronic pain: A review of the evidence. The Clinical Journal of Pain, 24(6), 469–478.
172. Tennant, F. (2010, January 1). Opioid treatment 10-year longevity survey final report. Practical Pain Management. Retrieved from http://www.practicalpainmanagement.com/treatments/pharmacological/opioids/opioid-treatment-10-year-longevity-survey-final-report
173. Hamza, M., Doleys, D., Wells, M., Weisbein, J., Hoff, J., Martin, M., et al. (2012). Prospective study of 3-year follow-up of low-dose intrathecal opioids in the management of chronic nonmalignant pain. Pain Medicine, 13(10), 1304–1313.
174. Chapman, C. R., Lipschitz, D. L., Angst, M. S., Chou, R., Densico, R. C., Donaldson, G. W., et al. (2010). Opioid pharmacotherapy for chronic non-cancer pain in the United States: A research guideline for developing an evidence-base [Opioid pharmacotherapy research guideline]. The Journal of Pain, 11(9), 807–829.
175. Manchikanti, L., Ailinani, H., Koyyalagunta, D., Datta, S., Singh, V., Eriator, I., et al. (2011). A systematic review of randomized trials of long-term opioid management for chronic non-cancer pain. Pain Physician, 14, 91–121.
176. Andrews, N. (2012, July 9). Moving pain treatments forward: An FDA public scientific workshop. Retrieved from http://www.painresearchforum.org/news/17889-moving-pain-treatments-forward-fda-public-scientific-workshop
177. Noble, M., Tregear, S. J., Treadwell, J. R., & Schoelles, K. (2008). Long-term opioid management for chronic noncancer pain: A systematic review and meta-analysis of efficacy and safety. Journal of Pain and Symptom Management, 35(2), 214–228.
178. Physicians for Responsible Opioid Prescribing. (n.d.). Cautious, evidence-based opioid prescribing. Retrieved from http://www.support-prop.org/educational/PROP_OpioidPrescribing.pdf
179. Von Korff, M., Kolodny, A., Deyo, R. A., & Chou, R. (2011). Long-term opioid therapy reconsidered. Annals of Internal Medicine, 155(5), 325–328.
180. Noble, M., Tregear, S. J., Treadwell, J. R., & Schoelles, K. (2008). Long-term opioid management for chronic noncancer pain: A systematic review and meta-analysis of efficacy and safety. Journal of Pain and Symptom Management, 35(2), 214–228.
181. Noble, M., Treadwell, J. R., Tregear, S. J., Coates, V. H., Wiffen, P. J., Akafomo, C., et al. (2010). Long-term opioid management for chronic non-cancer pain [Intervention review]. Cochrane Database of Systematic Reviews, 2010(1), CD006605.
182. Chapman, C. R., Lipschitz, D. L., Angst, M. S., Chou, R., Densico, R. C., Donaldson, G. W., et al. (2010). Opioid pharmacotherapy for chronic non-cancer pain in the United States: A research guideline for developing an evidence-base [Opioid pharmacotherapy research guideline]. The Journal of Pain, 11(9), 807–829.
183. Eriksen, J., Sjogren, P., Bruera, E., Ekhold, O., & Rasmussen, N. K. (2006). Critical issues on opioids in chronic non-cancer pain: An epidemiological study. PAIN, 125, 172–179.
184. Joranson, D. E. (2004). Improving availability of opioid pain medications: Testing the principle of balance in Latin America. Journal of Palliative Medicine, 7(1), 105–114.
185. Sjogren, P., Gronbaek, M., Peuckmann, V., & Ekholm, O. (2010) A population-based cohort study on chronic pain: The role of opioids. The Clinical Journal of Pain, 26(9), 763–769.
186. Ballantyne, J. C., & Shin, N. S. (2008). Efficacy of opioids for chronic pain: A review of the evidence. The Clinical Journal of Pain, 24(6), 469–478.
187. Katz, M. H. (2010). Long-term opioid treatment of nonmalignant pain: A believer loses his faith [Editorial]. Archives of General Medicine, 170(16), 1422–1423.
188. Foley, K. M., Fins, J. J., & Inturrisi, C. E. (2011). A true believer’s flawed analysis. Archives of Internal Medicine, 171(9), 867–868.
189. US Drug Enforcement Administration. (2012, April 17). Controlled substances by CSA schedule. Retrieved from http://www.deadiversion.usdoj.gov/schedules/orangebook/e_cs_sched.pdf
190. Office of Diversion Control, U.S. Department of Justice. (2013, May). List of controlled substances. Retrieved from http://www.deadiversion.usdoj.gov/schedules/#define
1. Leavitt, S. B. (2010). Intranasal naloxone for at-home opioid rescue. Practical Pain Management. Retrieved from http://www.practicalpainmanagement.com/treatments/pharmacological/opioids/intranasal-naloxone-home-opioid-rescue
2. Szalavitz, M. (2011, September 27). Drugs, risk and the myth of the “evil” addict [Blog post]. Retrieved from http://opinionator.blogs.nytimes.com/2011/09/27/drugs-risk-and-the-myth-of-the-evil-addict
3. Project Lazarus. (n.d.). Project Lazarus results for Wilkes County. Retrieved from http://www.projectlazarus.org/project-lazarus-results-wilkes-county
4. Albert, S., Brason, F. W., II, Sanford, C. K., Dasgupta, N., Graham, J., & Lovette, B. (2011). Project Lazarus: Community-based overdose prevention in rural North Carolina. Pain Medicine, 12(Supplement 2), S77–S85.
5. J. Dahl (personal communication, March 27, 2013).
6. Lazar, K. (2011, August 31). Progress seen in fight on heroin. The Boston Globe. Retrieved from http://articles.boston.com/2011-08-31/news/29949874_1_narcan-overdose-deaths-addicts
7. The Massachusetts Department of Public Health. (2012, April 25). The Massachusetts Department of Public Health opioid overdose prevention and reversal information sheet. Retrieved from http://www.mass.gov/eohhs/docs/dph/substance-abuse/naloxone-info.pdf
8. Centers for Disease Control and Prevention. (2012). Community-based opioid overdose prevention programs providing naloxone—United States, 2010. Morbidity and Mortality Weekly Report, 61(6), 101–105.
9. US Food and Drug Administration. (2011, November 22). Role of naloxone in opioid overdose fatality prevention; Public workshop, preliminary agenda. Retrieved from http://pain-topics.org/docs/FDA-NaloxoneMeeting-April2012.pdf
10. D. Carr (personal communication, April 23, 2012).
11. D. Carr (personal communication, April 23, 2012).
12. Johnson, K. (2012, April 12). Taking it to feel normal: My Oxycodone experience [Blog post]. Retrieved from http://commonhealth.wbur.org/2012/04/painkiller-addiction
13. D. Carr (personal communication, October 4, 2012).
14. J. Dahl (personal communication, March 27, 2013).
15. C. Garner (personal communication, March 16, 2011).
16. L. Webster (personal communication, May 25, 2011).
17. J. Kauffman (personal communication, February 23, 2011).
18. J. Kauffman (personal communication, May 13, 2012).
19. J. Dahl (personal communication, May 25, 2011).
20. J. Kauffman (personal communication, May 13, 2012).
21. MacArthur, G. J., Minozzi, S., Martin, N., Vickerman, P., Deren, S., Bruneau, J., et al. (2012). Opiate substitution treatment and HIV transmission in people who inject drugs: Systematic review and meta-analysis. British Medical Journal, 345, e5945.
22. Arbuck, D. M. (2011, April 6). Is buprenorphine effective for chronic pain? Retrieved from http://updates.pain-topics.org/2011/04/is-buprenorphineeffective-for-chronic.html
23. D. Carr (personal communication, April 23, 2012).
24. Arbuck, D. M. (2011, April 6). Is buprenorphine effective for chronic pain? Retrieved from http://updates.pain-topics.org/2011/04/is-buprenorphineeffective-for-chronic.html
25. L. Webster (personal communication, May 25, 2011).
26. S. B. Leavitt (personal communication, May 10, 2011).
27. Weiss, R. D., Potter, J. S., Fiellin, D. A., Byrne, M., Connery, H. S., Dickinson, W., et al. (2011). Adjunctive counseling during brief and extended buprenorphine-naloxone treatment for prescription opioid dependence. Archives of General Psychiatry, 68(12), 1238–1246.
28. Drugs.com. (n.d.). Butrans approval history. Retrieved from http://www.drugs.com/history/butrans.html
29. Ling, W., Casadonte, P., Bigelow, G., Kampman, K. M., Patkar, A., Bailey, G. L., et al. (2010). Buprenorphine implants for treatment of opioid dependence: A randomized clinical trial. Journal of the American Medical Association, 304(14), 1576–1583.
30. O’Connor, P. G. (2010). Advances in the treatment of opioid dependence: Continued progress and ongoing challenges [Editorial]. Journal of the American Medical Association, 304(14), 1612–1614.
31. Steiner, D., Munera, C., Hale, M., Ripa, S., & Landau, C. (2011). Efficacy and safety of buprenorphine transdermal system (BTDS) for chronic moderate to severe low back pain: A randomized, double-blind study. The Journal of Pain, 12(11), 1163–1172.
32. Arbuck, D. M. (2011, April 6). Is buprenorphine effective for chronic pain? Retrieved from http://updates.pain-topics.org/2011/04/is-buprenorphine-effective-for-chronic.html
33. Hitt, E. (2010, October 14). Once-monthly naltrexone approved for treatment of opioid addiction. Retrieved from http://www.medscape.com/viewarticle/730457?src=rss
34. P. Fine (personal communication, October, 2009).
35. Knotkova, H., Fine, P. G., & Portenoy, R. K. (2009). Opioid rotation: The science and the limitations of the equianalgesic dose table. Journal of Pain and Symptom Management, 38(3), 426–439.
36. Chou, R., Fanciullo, G. J., Fine, P. G., Adler, J. A., Ballantyne, J. C., Davies, P., et al. (2009). Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. The Journal of Pain, 10(2), 113–130.
37. Leavitt, S. B. (2009, November 21). Opioid rotation: Benefits, challenges, hazards. Retrieved from http://updates.pain-topics.org/2009/11/opioid-rotation-benefits-challenges.html
38. Arbuck, D. M. (2012, February 8). New views of opioid equivalency. Retrieved from http://updates.pain-topics.org/2012/02/new-views-onopioid-equivalency.html
39. Webster, L. R., & Fine, P. G. (2012). Overdose deaths demand a new paradigm for opioid rotation. Pain Medicine, 13(4), 571–574.
40. Webster, L. R., & Fine, P. G. (2012). Review and critique of opioid rotation practices and associated risks of toxicity. Pain Medicine, 13(4), 562–570.
41. Leavitt, S. B. (2012, April 5). New perspectives on safer opioid rotation. Retrieved from http://updates.pain-topics.org/2012/04/new-perspectives-on-safer-opioid.html
42. R. Twillman (personal communication, June 2, 2011).
43. Katz, N. (2008). Abuse-deterrent opioid formulations: Are they a pipe dream? Current Rheumatology Reports, 10(1), 11–18.
44. L. Webster (personal communication, February 17, 2011).
45. J. Heins (personal communication, May 15, 2012).
46. Eban, K. (2011, November 21). OxyContin: Purdue Pharma’s painful medicine. Retrieved from http://features.blogs.fortune.cnn.com/2011/11/09/oxycontin-purdue-pharma/
47. Purdue Pharma. (2002, June 27). Purdue Pharma implements national surveillance system to track diversion and abuse of controlled pain medications [Press release]. Retrieved from http://headaches.about.com/bl-radars.htm
48. Dart, R. (2011). RADARS system abuse/tamper deterrent formulations: 2011 update and analysis. Retrieved from http://www.radars.org/Portals/1/04_DartR_ADF_Update_distribution_20120502.pdf
49. Burke, J. (2011, May 16). The OxyContin reformulation: Is it working? Retrieved from http://www.pharmacytimes.com/publications/issue/2011/May2011/DrugDiversion-0511
50. Cicero, T. J., Ellis, M. S., & Surratt, H. L. (2012). Effect of abuse-deterrent formulation of OxyContin [Letter to the editor]. New England Journal of Medicine, 367, 187–198.
51. Leavitt, S. B. (2012, July 13). Abuse-deterrent opioids spawn upsurge in heroin. Retrieved from http://updates.pain-topics.org/2012/07/abuse-deterrent-opioids-spawn-upsurge.html
52. Leger, D. L. (2012, July 10). Opana abuse in USA overtakes OxyContin. Retrieved from http://www.usatoday.com/news/nation/story/2012-07-10/opana-painkiller-addiction/56137086/1#
53. EMBEDA. (n.d.). Important information for patients and prescribers. Retrieved from http://www.embeda.com
54. L. Webster (personal communication, February 17, 2011).
55. Drugs.com. (n.d.). Remoxy approval status. Retrieved from http://www.drugs.com/history/remoxy.html
56. Leavitt, S. B. (2011, August 12). Abuse-deterrent opioids; A better mousetrap? Retrieved from http://updates.pain-topics.org/2011/08/abuse-deterrent-opioids-better.html
57. National Institute of Drug Abuse. (2012, July 25). NIDA supports development of combined anti-heroin and HIV vaccine [Press release]. Retrieved from http://www.drugabuse.gov/news-events/news-releases/2012/07/nida-supports-development-combined-anti-heroin-hiv-vaccine-0
58. Payne, R., Anderson, E., Arnold, R., Duensing, L., Gilson, A. Green, C., et al. (2010). A rose by any other name: Pain contracts/agreements. American Journal of Bioethics, 10(11), 5–12.
59. Andrews, M. (2011, April 4). Some doctors require patients to sign contracts get opioid painkillers. The Washington Post. Retrieved from http://www.washingtonpost.com/national/health/some-doctors-require-patients-to-sign-contracts-get-opioid-painkillers/2011/03/29/AF7D31dC_story.html
60. Payne, R., Anderson, E., Arnold, R., Duensing, L., Gilson, A. Green, C., et al. (2010). A rose by any other name: Pain contracts/agreements. American Journal of Bioethics, 10(11), 5–12.
61. Hariharan, J., Lamb, G. C., & Neuner, J. M. (2007). Long-term opioid contract use for chronic pain management in primary care practice: A five year experience. Journal of General Internal Medicine, 22(4), 485–490.
62. Starrels, J. L., Becker, W. C., Alford, D. P., Kapoor, A., Williams, A. R., & Turner, B. J. (2010). Systematic review: Treatment agreements and urine drug testing to reduce opioid misuse in patients with chronic pain. Annals of Internal Medicine, 152(11), 712–720.
63. R. Jamison (personal communication, February 14, 2011).
64. Katz, M. H. (2010). Long-term opioid treatment of nonmalignant pain: A believer loses his faith [Editorial]. Archives of General Medicine, 170(16), 1422–1423.
65. Collen, M. (2009). Opioid contracts and random drug testing for people with chronic pain—think twice. Journal of Law, Medicine & Ethics, 37(4), 841–845.
66. Centers for Disease Control and Prevention. (2010, July). Unintentional drug poisoning in the United States. Retrieved from http://www.cdc.gov/HomeandRecreationalSafety/pdf/poison-issue-brief.pdf
67. Federation of State Medical Boards of the United States. (2004). Model policy for the use of controlled substances for the treatment of pain. Retrieved from http://www.fsmb.org/pdf/2004_grpol_Controlled_Substances.pdf
68. Chou, R., Fanciullo, G. J., Fine, P. G., Adler, J. A., Ballantyne, J. C., Davies, P., et al. (2009). Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. The Journal of Pain, 10(2), 113–130.
69. R. Twillman (personal communication, June 2, 2011).
70. Collen, M. (2011). The Fourth Amendment and random drug testing of people with chronic pain. Journal of Pain & Palliative Care Pharmacology, 25, 42–48.
71. Becker, W. C., Starrels, J. L., Heo, M., Li, X., Weiner, M. G., & Turner, B. J. (2011). Racial differences in primary care opioid risk reduction strategies. Annals of Family Medicine, 9(3), 219–225.
72. Michna, E., Jamison, R. N., Pham, L-D., Ross, E. L., Janfaza, D., Nedeljkovic, S. S., et al. (2007). Urine toxicology screening among chronic pain patients on opioid therapy: Frequency and predictability of abnormal findings. Clinical Journal of Pain, 23(2), 173–179.
73. Quest Diagnostics. (2012, April 27). Three in five Americans misuse their prescription drugs, finds national study of prescription medication lab testing [Press release]. Retrieved from http://markets.on.nytimes.com/research/stocks/news/press_release.asp?docTag=201204271507PR_NEWS_USPRX____NY95661&feedID=600&press_symbol=89411
74. Quest Diagnostics. (2012). Prescription drug monitoring report 2012. Pre scription drug misuse in America—laboratory insights into the new drug epidemic. Retrieved from http://www.questdiagnostics.com/dms/Documents/health-trends/PDF-MI3040_PDM-Report_24638_FIN_Digital_4-20-12/PDF%20MI3040_PDM%20Report_24638_FIN_Digital_4-20-12.pdf
75. West, R., Pesce, A., West, C., Crews, B., Mikel, C., Rosenthal, M., et al. (2010). Observations of medication compliance by measurement of urinary drug concentrations in a pain management population. Journal of Opioid Management, 6(4), 253–257.
76. Heit, H. (2010). Tackling the difficult problem of prescription opioid misuse [Editorial]. Annals of Internal Medicine, 152(11), 747–748.
77. Collen, M. (2009). Opioid contracts and random drug testing for people with chronic pain—think twice. Journal of Law, Medicine & Ethics, 37(4), 841–845.
78. S. B. Leavitt (personal communication, May 19, 2012).
79. Leavitt, S. B. (2011, March 3). Biased UDT research distorts opioid misuse, again. Retrieved from http://updates.pain-topics.org/2011/03/biased-udt-research-distorts-opioid.html
80. Leavitt, S. B. (2010, September 11). Another UDT study distorts opioid noncompliance. Retrieved from http://updates.pain-topics.org/2010/09/another-udt-study-distorts-opioid.html
81. Anson, P. (2012, April 30). Industry funded study promotes more drug testing. Retrieved from http://americannewsreport.com/industry-funded-study-promotes-more-drug-testing-8814015.html
82. Cuoto, J. E., Peppin, J. F., Fine, P. G., Passik, S. D., & Goldfarb, N. I. (2012, February). Developing recommendations for urine drug monitoring for patients on long-term opioid therapy. Paper presented at the 2012 American Academy of Pain Medicine Annual meeting, Palm Springs, CA. Abstract retrieved from http://www.painmed.org/2012posters/abstract-215/
83. United States ex rel. Maul v. Ameritox, LLC, No. 8:07-cv-953-T-26EAJ (M.D. Fla. 2010).
84. Collen, M. (2012). Profit-driven drug testing. Journal of Pain and Palliative Care Pharmacology, 26, 13–17.
85. Department of Justice. (2010, November 16). Ameritox, Ltd. Agrees to pay $16.3 million to resolve kickback claims associated with laboratory testing services. Retrieved from http://pharmacychoice.us/News/article.cfm?Article_ID=653009
86. Millennium Laboratories. (2012, June 13). Millennium laboratories wins lawsuit; federal jury finds Ameritox repeatedly lied to physicians regarding Rx Guardian and Rx Guardian CD [Press release]. Retrieved from http://www.bizjournals.com/sanfrancisco/prnewswire/press_releases/California/2012/06/13/LA24201
87. Ameritox. (2012, June 15). Science behind Ameritox pain medication monitoring products emerges from trial unscathed [Press release]. Retrieved from http://www.ameritox.com/science-behind-ameritox-pain-medication-monitoring-products-emerges-from-trial-unscathed/
88. R. Twillman (personal communication, June 2, 2011).
89. S. B. Leavitt (personal communication, May 19, 2012).
90. Meadway, C., George, S., & Braithwaite, R. (1998). Opiate concentrations following the ingestion of poppy products—evidence for “the poppy seed defence.” Forensic Science International, 96(1), 29–38.
91. Alliance of States with Prescription Monitoring Programs. (n.d.). Prescription monitoring frequently asked questions (FAQ). Retrieved from http://www.pmpalliance.org/content/prescription-monitoring-frequently-asked-questions-faq
92. Leavitt, S. B. (2011, February 24). Rx monitoring doesn’t stem opioid overdose deaths. Retrieved from http://updates.pain-topics.org/2011/02/rx-monitoring-doesnt-stem-opioid.html
93. Simeone, R., & Holland, L. (2006, September 1). An evaluation of prescription drug monitoring programs [Executive summary]. Retrieved from https://www.bja.gov/publications/pdmpexecsumm.pdf
94. Executive Office of the President of the United States. (2011). Epidemic: Responding to America’s prescription drug abuse crisis (p. 5). Retrieved from http://www.whitehouse.gov/sites/default/files/ondcp/issues-content/prescription-drugs/rx_abuse_plan_0.pdf
95. R. Twillman (personal communication, October 8, 2012).
96. Wang, J., & Christo, P. J. (2009). The influence of prescription monitoring programs on chronic pain management. Pain Physician, 12, 507–515.
97. Pain & Policy Studies Group. (n.d.). Prescription monitoring programs (PMPs). Retrieved from http://www.painpolicy.wisc.edu/domestic/pmp.htm
98. Simeone, R., & Holland, L. (2006, September 1). An evaluation of prescription drug monitoring programs [Executive summary]. Retrieved from https://www.bja.gov/publications/pdmpexecsumm.pdf
99. Leavitt, S. B. (2011, February 24). Rx monitoring doesn’t stem opioid overdose deaths. Retrieved from http://updates.pain-topics.org/2011/02/rx-monitoring-doesnt-stem-opioid.html
100. Gilson, A., Twillman, R., Dahl, J., & Fishman, S. (2010, May 7). Prescription Monitoring Programs’ impact on medication diversion and availability: What do we know and where should we go? Paper presented at the 29th Annual Scientific Meeting of the American Pain Society Meeting, Baltimore, MD.
101. Katz, N., Houle, B., Fernandez, K. C., Kreiner, P., Thomas, C. P., Kim, M., et al. (2008). Update on prescription monitoring in clinical practice: A survey study of prescription monitoring program administrators. Pain Medicine, 9(5), 587–594.
102. United States General Accounting Office. (2002, May 17). Prescription drugs: State monitoring programs provide useful tool to reduce diversion (Report No. GAO-02–634). Retrieved from http://www.gao.gov/assets/240/234687.pdf
103. Simeone, R., & Holland, L. (2006, September 1). An evaluation of prescription drug monitoring programs [Executive summary]. Retrieved from https://www.bja.gov/publications/pdmpexecsumm.pdf
104. Katz, N., Panas, L., Kim, M., Audet, A. D., Bilansky, A., Eadie, J., et al. (2010). Usefulness of prescription monitoring programs for surveillance—analysis of Schedule II opioid prescription data in Massachusetts, 1996–2006. Pharmacoepidemiology and Drug Safety, 19(2), 115–123.
105. Gilson, A., Twillman, R., & Dahl, J. (2010, May 7). Prescription Monitoring Programs’ impact on medication diversion and availability: What do we know and where should we go? Paper presented at the 29th Annual Scientific Meeting of the American Pain Society Meeting, Baltimore, MD.
106. Walter, S. (2012, April 7). Meager participation hobbles drug oversight. The New York Times. Retrieved from http://www.nytimes.com/2012/04/08/us/poor-participation-hobbles-californias-drug-oversight.html?pagewanted=all
107. Twillman, R. K. (2003). Report from the 10th World Congress on Pain. Journal of Pain and Palliative Care Pharmacotherapy, 17(2), 83–88.
108. Twillman, R. K. (2006). Impact of prescription monitoring programs on prescription patterns and indicators of opioid abuse. The Journal of Pain, 7(4), S6.
109. R. Twillman (personal communication, June 2, 2011).
110. Kerlikowske, G., Jones, C. M., LaBelle, R. M., & Condon, T. P. (2011). Prescription drug monitoring programs—lack of effectiveness or a call to action? [Editorial]. Pain Medicine, 12, 687–689.
111. Paulozzi L. J., Kilbourne E. M., & Desai, H. A. (2011). Prescription drug monitoring programs and death rates from drug overdose. Pain Medicine, 12(5), 747–754.
112. Reifler, L. M., Droz, D., Bailey, J. E., Schnoll, S. H., Fant, R., Dart, R. C., et al. (2012). Do prescription monitoring programs impact state trends in opioid abuse/misuse? Pain Medicine, 13( 3), 434–442.
113. C. Steinberg. (2012, July 20). Massachusetts Pain Initiative testimony on proposed regulations to enhance the Prescription Monitoring Program (105CMR 700.000 & 105 CMR 701.000) [Personal communication].
114. US Food and Drug Administration. (n.d.). Approved risk evaluation and mitigation strategies (REMS): Currently approved individual REMS. Retrieved from http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111350.htm
115. US Food and Drug Administration. (n.d.). List of long-acting and extended-release opioid products required to have an opioid REMS. Retrieved from http://www.fda.gov/Drugs/DrugSafety/InformationbyDrugClass/ucm251735.htm
116. J. Dahl (personal communication, July 27, 2012).
117. The White House, Office of National Drug Control Policy. (2011, April 19). Obama administration releases action plan to address national prescription drug abuse epidemic; announces FDA action requiring drug makers to develop education program for prescribers about safe use of opioids [Press release]. Retrieved from http://www.whitehouse.gov/ondcp/news-releases-remarks/obama-administration-releases-action-plan
118. Executive Office of the President of the United States. (2011). Epidemic: Responding to America’s prescription drug abuse crisis (p. 5). Retrieved from http://www.whitehouse.gov/sites/default/files/ondcp/issues-content/prescription-drugs/rx_abuse_plan_0.pdf
119. Leavitt, S. B. (2011, April 20). U.S. FDA releases long-awaited opioid-REMS. Retrieved from http://updates.pain-topics.org/2011/04/us-fda-releases-long-awaited-opioid.html
120. Department of Health and Human Services, Food and Drug Administration. (2009). Risk evaluation and mitigation strategies for certain opioid drugs; notice of public meeting. Federal Register, 74(74), 17967–17970. Retrieved from http://www.gpo.gov/fdsys/pkg/FR-2009-04-20/pdf/E9-8903.pdf
121. US Food and Drug Administration. (2012, July 9). FDA introduces new safety measures for extended-release and long-acting opioid medications [Press release]. Retrieved from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm310870.htm
122. J. Dahl (personal communication, July 27, 2012).
123. Nelson, L. S., & Perrone, J. (2012). Curbing the opioid epidemic in the United States—the risk evaluation and mitigation strategy (REMS). Journal of the American Medical Association, 308(5), 457–458.
124. US Food and Drug Administration Consumer Health Information. (2009, February 23). A guide to safe use of pain medicine. Retrieved from http://www.fda.gov/downloads/ForConsumers/ConsumerUpdates/ucm095742.pdf
125. US Food and Drug Administration. (n.d.). Approved risk evaluation and mitigation strategies (REMS): Currently approved individual REMS. Retrieved from http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm111350.htm
126. US Food and Drug Administration. (2012, July 9). FDA introduces new safety measures for extended-release and long-acting opioid medications [Press release]. Retrieved from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm310870.htm
127. Leavitt, S. B. (2012, July 10). U.S. FDA launches the long-awaited opioid REMS. Retrieved from http://updates.pain-topics.org/2012/07/us-fda-launches-long-awaited-opioid.html
128. US Food and Drug Administration. (2012, July 9). FDA introduces new safety measures for extended-release and long-acting opioid medications [Press release]. Retrieved from http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm310870.htm
129. S. B. Leavitt (personal communication, May 19, 2012).
130. J. Dahl (personal communication, July 27, 2012).
131. H. Neuman (personal communication, April 5, 2011).
132. L. Webster (personal communication, May 13, 2012).
133. Michna, E., Ross, E. L., Hynes, W. L., Nedeljkovic, S. S., Soumekh, S., Janfaza, D., et al. (2004). Predicting aberrant drug behavior in patients treated for chronic pain: Importance of abuse history. Journal of Pain and Symptom Management, 28(3), 250–258.
134. Chou, R., Fanciullo, G. J., Fine, P. G., Adler, J. A., Ballantyne, J. C., Davies, P., et al. (2009). Clinical guidelines for the use of chronic opioid therapy in chronic noncancer pain. The Journal of Pain, 10(2), 113–130.
135. American Pain Society. (2009, February 10). New guidelines for prescribing opioid pain drugs published [Press release]. Retrieved from http://www.ampainsoc.org/press/2009/downloads/20090210.pdf
136. Federation of State Medical Boards of the United States. (2004). Model policy for the use of controlled substances for the treatment of pain. Retrieved from http://www.fsmb.org/pdf/2004_grpol_Controlled_Substances.pdf
137. Schiff, G. D., Galanter, W. L., Duhig, J., Lodolce, A. E., Koronowski, M. J., & Lambert, B. L. (2011). Principles of conservative prescribing [Review article]. Archives of Internal Medicine, 171(16), 1433–1440.
138. Physicians for Responsible Opioid Prescribing. (n.d.). Cautious, evidence-based opioid prescribing. Retrieved from http://www.support-prop.org/educational/PROP_OpioidPrescribing.pdf
139. Leavitt, S. B. (2010, September). Common opioid pain relievers. Retrieved from http://opioids911.org/opioidproducts.php
140. L. Webster (personal communication, May 14, 2012).
141. Utah Department of Health. (2011). Utah’s winnable health battles: Prescription drug misuse, abuse and overdose deaths. Retrieved from https://health.utah.gov/phi/getfile.php?id=236
142. Katz, M. H. (2010). Long-term opioid treatment of nonmalignant pain: A believer loses his faith [Editorial]. Archives of General Medicine, 170(16), 1422–1423.
143. Foley, K. M., Fins, J. J., & Inturrisi, C. E. (2011). A true believer’s flawed analysis. Archives of Internal Medicine, 171(9), 867–868.
144. Physicians for Responsible Opioid Prescribing. (2012, July 25). Citizen petition (Document ID: FDA-2012-P-0818-0001). Retrieved from http://www.regulations.gov/#!documentDetail;D=FDA-2012-P-0818-0001
145. Bono Mack, M. (2012, July 26). [Letter to Margaret Hamburg, M.D., Commissioner, Food and Drug Administration]. Retrieved from http://bono.house.gov/uploadedfiles/fda_opioid_labels_letter7_26_12.pdf
146. Public Citizen. (2012, July 25). Doctors, researchers and health officials call on FDA to change labels on opioid painkillers to deter misprescribing [Press release]. Retrieved from http://www.citizen.org/pressroom/pressroomredirect.cfm?ID=3674
147. Physicians for Responsible Opioid Prescribing. (2012, July 25). Citizen petition (Document ID: FDA-2012-P-0818-0001). Retrieved from http://www.regulations.gov/#!documentDetail;D=FDA-2012-P-0818-0001
148. Twillman, R. (2012, August 2). Group petitions FDA to change opioid label. Retrieved from http://updates.pain-topics.org/2012/08/group-petitions-fda-to-change-opioid.html